


**CUMULATIVE
SUPPLEMENT 3
APRIL 2005**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

25th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

25th EDITION

Cumulative Supplement 4

April 2005

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition	v
1.4 Report of Counts for the Prescription Drug Product List	v
1.5 Cumulative Supplement Legend	vi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

25th EDITION

**CUMULATIVE SUPPLEMENT 4
April 2005**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

CELLTECH PHARMACEUTICALS INC
(CELLTECH PHARMS
FUJISAWA HEALTHCARE

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

UCB PHARMA INC
(UCB)
ASTELLAS PHARMA US INC

(FUJISAWA HLTHCARE)	(ASTELLAS)
SHIRE LABORATORIES INC	SHIRE DEVELOPMENT INC
(SHIRE LABS)	(SHIRE)
SHIRE PHARMACEUTICAL DEVELOPMENT INC	SHIRE DEVELOPMENT INC
(SHIRE PHARM)	(SHIRE)
YAMANOUCHI PHARMA AMERICA INC	ASTELLAS PHARMA US INC
(YAMANOUCHI)	(ASTELLAS)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB) <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and

effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2004	MAR 2005	JUN 2005	SEP 2005
DRUG PRODUCTS LISTED	11082	11184		
SINGLE SOURCE	2427 (21.9%)	2437 (21.8%)		
MULTISOURCE	8547 (77.1%)	8637 (77.2%)		
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	8428 (75.4%)		
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	209 (1.9%)		
EXCEPTIONS ¹	108 (1.0%)	110 (1.0%)		
NEW MOLECULAR ENTITIES APPROVED	9	2		
NUMBER OF APPLICANTS	625	631		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

PRESCRIPTION DRUG PRODUCT LIST - 25TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLIMENT 4 - April 2005

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, APAP, AND CAFFEINE

AB WATSON LABS 325MG;50MG;40MG N89536 001 Feb 16, 1988 Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND TRAMADOL HCL

AB KALI LABS 325MG;37.5MG N76475 001 Apr 21, 2005 Mar NEWA

ULTRACET

AB + ORTHO MCNEIL PHARM 325MG;37.5MG N21123 001 Aug 15, 2001 Mar CFTG

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT + MORTON GROVE 2% N40166 001 Jul 26, 1996 Jan CRLD

AT VINTAGE 2% N40607 001 Feb 24, 2005 Feb NEWA

VOSOL

@ MEDPOINTE PHARM HLC 2% N12179 001 Jan DISC

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ UCB 8MG;60MG N19806 001 Mar 25, 1994 Mar CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB TEVA PHARMS 200MG N74914 001 Nov 26, 1997 Mar CAHN

TABLET; ORAL

ACYCLOVIR

AB TEVA PHARMS 400MG N75021 001 Mar 18, 1998 Mar CAHN

AB 800MG N75021 002 Mar 18, 1998 Mar CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

@ ABBOTT EQ 50MG BASE/ML N75114 001 Jul 26, 1999 Feb DISC

ADENOSINE

INJECTABLE; INJECTION

ADENSOINE

>A> AP AM PHARM 3MG/ML N77133 001 Apr 27, 2005 Apr NEWA

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN + DEY EQ 0.083% BASE N72652 001 Feb 21, 1992 Jan CRLD

TABLET; ORAL

ALBUTEROL SULFATE

>A> AB + MYLAN EQ 2MG BASE N72894 002 Jan 17, 1991 Apr CMS1

ALENDRONATE SODIUM

SOLUTION; ORAL
FOSAMAX
>D> + MERCK EQ 70MG ACID/75ML N21575 001 Sep 17, 2003 Apr CPOT
>A> + EQ 70MG BASE/75ML N21575 001 Sep 17, 2003 Apr CPOT

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL
FOSAMAX PLUS D
>A> + MERCK EQ 70MG BASE;2,800 IU N21762 001 Apr 07, 2005 Apr NEWA

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM
SCHWARZ PHARMA 0.25MG N21726 001 Jan 19, 2005 Jan NEWA
0.5MG N21726 002 Jan 19, 2005 Jan NEWA
1MG N21726 003 Jan 19, 2005 Jan NEWA
+ 2MG N21726 004 Jan 19, 2005 Jan NEWA

ALPROSTADIL

INJECTABLE; INJECTION
EDEX
>D> + SCHWARZ PHARMA 0.01MG/VIAL N20649 005 Jul 30, 1998 Apr CTEC
>A> AP + 0.01MG/VIAL N20649 005 Jul 30, 1998 Apr CTEC
>D> + 0.02MG/VIAL N20649 006 Jul 30, 1998 Apr CTEC
>A> AP + 0.02MG/VIAL N20649 006 Jul 30, 1998 Apr CTEC
>D> + 0.04MG/VIAL N20649 007 Jul 30, 1998 Apr CTEC
>A> AP + 0.04MG/VIAL N20649 007 Jul 30, 1998 Apr CTEC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
AA TEVA PHARMS 50MG/5ML N73115 001 Aug 23, 1991 Mar CAHN

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN 7%
HOSPIRA 7% (7GM/100ML) N17673 002 Mar CMFD
AMINOSYN 8.5%
HOSPIRA 8.5% (8.5GM/100ML) N17673 004 Mar CMFD

AMIODARONE

INJECTABLE; INTRAVENOUS
AMIODARONE HCL
AP APOTEX 50MG/ML N77161 001 Apr 20, 2005 Mar NEWA

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL
AP + AM PHARM PARTNERS 50MG/ML N75761 001 Oct 15, 2002 Mar CRLD
AP + APOTEX 50MG/ML N76394 001 Apr 25, 2003 Mar CRLD
AP + BEDFORD 50MG/ML N76018 001 Oct 15, 2002 Mar CRLD
AP + BEDFORD LABS 50MG/ML N76299 001 Oct 24, 2002 Mar CRLD
AP + BEN VENUE 50MG/ML N76088 001 Oct 15, 2002 Mar CRLD
AP + BIONICHE (CANADA) 50MG/ML N76217 001 Oct 15, 2002 Mar CRLD

INJECTABLE; INJECTION

AMIODARONE HCL

AP + MAYNE PHARMA USA	50MG/ML	N76108 001 Oct 15, 2002 Mar CRLD
AP + SICOR PHARMS	50MG/ML	N76163 001 Sep 05, 2003 Mar CRLD

TABLET; ORAL

AMIODARONE HCL

AB AUROSAL PHARMS	200MG	N77069 001 Apr 08, 2005 Mar NEWA
AB	400MG	N77069 002 Apr 08, 2005 Mar NEWA
AB TARO	100MG	N75424 002 Dec 18, 2002 Mar CTEC
AB TEVA PHARMS	200MG	N74739 001 Nov 30, 1998 Mar CAHN
PACERONE		
AB UPSHER SMITH	100MG	N75135 002 Apr 12, 2005 Mar NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

TRIMOX

>D> @ APOTHECON	50MG/ML	N61886 001 Apr CMFD
>A> AB	50MG/ML	N61886 001 Apr CMFD
>D> @	125MG/5ML	N61886 002 Apr CMFD
>A> AB	125MG/5ML	N61886 002 Apr CMFD
>D> @	250MG/5ML	N61886 003 Apr CMFD
>A> AB	250MG/5ML	N61886 003 Apr CMFD

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB HIKMA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65191 002 Jan 25, 2005 Jan NEWA
AB	400MG/5ML;EQ 57MG BASE/5ML	N65191 001 Jan 25, 2005 Jan NEWA

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB TEVA	200MG;EQ 28.5MG BASE	N65205 001 Feb 09, 2005 Jan NEWA
AB	400MG;EQ 57MG BASE	N65205 002 Feb 09, 2005 Jan NEWA

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP INSTITUTO BIOCHEMICO	EQ 125MG BASE/VIAL	N62797 001 Jul 12, 1993 Jan CMFD
AP	EQ 2GM BASE/VIAL	N62797 002 Jul 12, 1993 Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB SHIRE	EQ 0.5MG BASE	N20333 001 Mar 14, 1997 Mar CFTG
AB +	EQ 1MG BASE	N20333 002 Mar 14, 1997 Mar CFTG

ANAGRELIDE HCL

AB BARR	EQ 0.5MG BASE	N76530 001 Apr 18, 2005 Mar NEWA
AB	EQ 1MG BASE	N76530 002 Apr 18, 2005 Mar NEWA
AB EON	EQ 0.5MG BASE	N76683 001 Apr 18, 2005 Mar NEWA
AB	EQ 1MG BASE	N76683 002 Apr 18, 2005 Mar NEWA
AB IMPAX LABS	EQ 0.5MG BASE	N76910 001 Apr 18, 2005 Mar NEWA
AB	EQ 1MG BASE	N76910 002 Apr 18, 2005 Mar NEWA
AB IVAX PHARMS	EQ 0.5MG BASE	N76468 001 Apr 18, 2005 Mar NEWA
AB	EQ 1MG BASE	N76468 002 Apr 18, 2005 Mar NEWA
AB MYLAN	EQ 0.5MG BASE	N76811 001 Apr 18, 2005 Mar NEWA
AB	EQ 1MG BASE	N76811 002 Apr 18, 2005 Mar NEWA
AB ROXANE	EQ 0.5MG BASE	N76489 001 Apr 18, 2005 Mar NEWA

CAPSULE; ORAL

ANAGRELIDE HCL

AB	ROXANE	EQ 1MG BASE	N76489 002	Apr 18, 2005	Mar	NEWA
AB	WATSON LABS	EQ 0.5MG BASE	N76417 001	Apr 18, 2005	Mar	NEWA
AB		EQ 1MG BASE	N76417 002	Apr 18, 2005	Mar	NEWA

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	N73457 002	Apr 26, 1999	Mar	CTEC
AB	TEVA PHARMS	50MG	N74120 001	Feb 24, 1995	Mar	CAHN
AB		100MG	N74120 002	Feb 24, 1995	Mar	CAHN
AB	ZYDUS PHARMS USA	25MG	N76900 001	Jan 28, 2005	Jan	NEWA
AB		50MG	N76900 002	Jan 28, 2005	Jan	NEWA
AB		100MG	N76900 003	Jan 28, 2005	Jan	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY	80MG	N21411 007	Feb 14, 2005	Feb	NEWA
	100MG	N21411 008	Feb 14, 2005	Feb	NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

>D>	VANCERIL					
>D>	+ SCHERING	0.042MG/INH	N17573 001		Apr	DISC
>A>	@	0.042MG/INH	N17573 001		Apr	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

@ HOLLISTER STIER LABS	60UMOLAR	N50114 001		Mar	DISC
------------------------	----------	------------	--	-----	------

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	TEVA PHARMS	EQ 0.05% BASE	N71882 001	Jun 06, 1988	Mar	CAHN
	OINTMENT; TOPICAL					
	ALPHATREX					
	@ SAVAGE LABS	EQ 0.05% BASE	N19143 001	Sep 04, 1984	Jan	DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	TEVA PHARMS	EQ 0.1% BASE	N71883 001	Apr 22, 1988	Mar	CAHN
----	-------------	--------------	------------	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

DUVOID

>D>	@ WELLSPRING PHARM	50MG	N85882 003		Apr	CMFD
>A> AA		50MG	N85882 003		Apr	CMFD

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	TEVA PHARMS	5MG	N75644 001	Jun 26, 2001	Mar	CAHN
----	-------------	-----	------------	--------------	-----	------

TABLET; ORAL

BISOPROLOL FUMARATE

AB TEVA PHARMS 10MG N75644 002 Jun 26, 2001 Mar CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

XIBROM

+ ISTA PHARMS 0.09% N21664 001 Mar 24, 2005 Mar NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

AB MYLAN EQ 5MG BASE N77226 001 Apr 04, 2005 Mar NEWA

PARLODEL

AB + NOVARTIS EQ 5MG BASE N17962 002 Mar 01, 1982 Mar CTEC

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP BEDFORD EQ 0.3MG BASE/ML N76931 001 Mar 02, 2005 Feb NEWA

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

>D> + BERTEK PHARMS 1% N20524 001 Oct 18, 1996 Apr CAHN

>A> + MYLAN BERTEK 1% N20524 001 Oct 18, 1996 Apr CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

BR G AND W LABS 100MG;2MG N86557 001 Oct 04, 1983 Feb CMFD

CAPTOPRIL

TABLET; ORAL

Captopril

AB TEVA PHARMS 12.5MG N74462 001 Feb 13, 1996 Mar CAHN

AB 25MG N74462 002 Feb 13, 1996 Mar CAHN

AB 50MG N74462 003 Feb 13, 1996 Mar CAHN

AB 100MG N74462 004 Feb 13, 1996 Mar CAHN

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

@ TARO

100MG/5ML

N75875 001 Dec 21, 2000 Mar DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP EON 50MG/VIAL N76959 001 Mar 18, 2005 Mar NEWA

AP 150MG/VIAL N76959 002 Mar 18, 2005 Mar NEWA

AP 450MG/VIAL N76959 003 Mar 18, 2005 Mar NEWA

CEFACLOR

CAPSULE; ORAL

CECLOR

@ LILLY

EQ 250MG BASE

N50521 001

Mar DISC

CAPSULE; ORAL

CECLR					
@ LILLY	EQ 500MG BASE	N50521 002	Mar	DISC	
CEFACLOR					
AB + RANBAXY	EQ 500MG BASE	N64156 002	Aug 28, 1997	Mar	CRLD
FOR SUSPENSION; ORAL					
>D> CECLR					
>D> AB CEPH INTL	EQ 125MG BASE/5ML	N62206 001	Apr	CTNA	
>D> AB	EQ 187MG BASE/5ML	N62206 003	Apr 20, 1988	Apr	CTNA
>D> AB	EQ 250MG BASE/5ML	N62206 002	Apr	CTNA	
>D> AB	EQ 375MG BASE/5ML	N62206 004	Apr 20, 1988	Apr	CTNA
AB	EQ 375MG BASE/5ML	N62206 004	Apr 20, 1988	Mar	CRLD
@ LILLY	EQ 125MG BASE/5ML	N50522 001	Mar	DISC	
@	EQ 250MG BASE/5ML	N50522 002	Mar	DISC	
>A> CEFACLOR					
>A> AB CEPH INTL	EQ 125MG BASE/5ML	N62206 001	Apr	CTNA	
>A> AB	EQ 187MG BASE/5ML	N62206 003	Apr 20, 1988	Apr	CTNA
>A> AB	EQ 250MG BASE/5ML	N62206 002	Apr	CTNA	
>A> AB	EQ 375MG BASE/5ML	N62206 004	Apr 20, 1988	Apr	CTNA
AB + RANBAXY	EQ 375MG BASE/5ML	N64155 001	Oct 02, 1997	Mar	CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATETABLET; ORAL

CEFADROXIL					
>D> @ IVAX PHARMS	EQ 1GM BASE	N62774 001	Apr 08, 1987	Apr	CMFD
>A> AB	EQ 1GM BASE	N62774 001	Apr 08, 1987	Apr	CMFD

CEFAZOLIN SODIUMINJECTABLE; INJECTIONCEFAZOLIN SODIUM

AP + AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998	Mar	CRLD
AP +	EQ 1GM BASE/VIAL	N64169 002	Aug 14, 1998	Mar	CRLD
AP +	EQ 10GM BASE/VIAL	N64170 001	Mar 18, 1998	Mar	CRLD
>A> AP ORCHID HLTHCARE	EQ 500MG BASE/VIAL	N65226 001	Apr 21, 2005	Apr	NEWA
>A> AP	EQ 1GM BASE/VIAL	N65226 002	Apr 21, 2005	Apr	NEWA

CEFTRIAKONE SODIUMINJECTABLE; IM-IVCEFTRIAKONE

>A> AP SANDOZ	EQ 250MG BASE/VIAL	N65169 001	May 09, 2005	Apr	NEWA
>A> AP	EQ 500MG BASE/VIAL	N65169 002	May 09, 2005	Apr	NEWA
>A> AP	EQ 1GM BASE/VIAL	N65169 003	May 09, 2005	Apr	NEWA
>A> AP	EQ 2GM BASE/VIAL	N65169 004	May 09, 2005	Apr	NEWA

INJECTABLE; INJECTIONCEFTRIAKONE

>A> AP SANDOZ	EQ 1GM BASE/VIAL	N65204 001	May 03, 2005	Apr	NEWA
>A> AP	EQ 2GM BASE/VIAL	N65204 002	May 03, 2005	Apr	NEWA
>A> AP	EQ 10GM BASE/VIAL	N65168 001	May 17, 2005	Apr	NEWA

>A> CEFTRIAKONE AND DEXTROSE IN DUPLEX CONTAINER

>A> AP + B BRAUN	EQ 1GM BASE/VIAL	N50796 001	Apr 20, 2005	Apr	NEWA
>A> AP +	EQ 2GM BASE/VIAL	N50796 002	Apr 20, 2005	Apr	NEWA

ROCEPHIN

>D> HLR	EQ 250MG BASE/VIAL	N63239 001	Aug 13, 1993	Apr	DISC
>A> @	EQ 250MG BASE/VIAL	N63239 001	Aug 13, 1993	Apr	DISC
>D>	EQ 500MG BASE/VIAL	N63239 002	Aug 13, 1993	Apr	DISC
>A> @	EQ 500MG BASE/VIAL	N63239 002	Aug 13, 1993	Apr	DISC
>D> +	EQ 1GM BASE/VIAL	N62654 002	Apr 30, 1987	Apr	CFTG

INJECTABLE; INJECTION

ROCEPHIN

>A>	AP	+	HLR	EQ 1GM BASE/VIAL	N62654 002	Apr 30, 1987	Apr	CFTG
		+		EQ 1GM BASE/VIAL	N62654 002	Apr 30, 1987	Mar	CRLD
>D>				EQ 1GM BASE/VIAL	N63239 003	Aug 13, 1993	Apr	DISC
>A>		@		EQ 1GM BASE/VIAL	N63239 003	Aug 13, 1993	Apr	DISC
>D>				EQ 2GM BASE/VIAL	N62654 003	Apr 30, 1987	Apr	CFTG
>A>	AP	+		EQ 2GM BASE/VIAL	N62654 003	Apr 30, 1987	Apr	CFTG
>D>		+		EQ 10GM BASE/VIAL	N50585 005	Dec 21, 1984	Apr	CFTG
>A>	AP	+		EQ 10GM BASE/VIAL	N50585 005	Dec 21, 1984	Apr	CFTG

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

>D>		+	B BRAUN	EQ 15MG BASE/ML	N50780 001	Feb 21, 2001	Apr	CPOT
>A>	AP	+		EQ 750MG BASE/VIAL	N50780 001	Feb 21, 2001	Apr	CPOT
>D>		+		EQ 30MG BASE/ML	N50780 002	Feb 21, 2001	Apr	CPOT
>A>	AP	+		EQ 1.5GM BASE/VIAL	N50780 002	Feb 21, 2001	Apr	CPOT

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

		@	APOTHECON	EQ 250MG BASE	N63186 001	Dec 30, 1994	Mar	DISC
		@		EQ 500MG BASE	N63186 002	Dec 30, 1994	Mar	DISC
AB			BELCHER	EQ 250MG BASE	N62713 001	Jul 15, 1988	Jan	CAHN
AB				EQ 500MG BASE	N62713 002	Jul 15, 1988	Jan	CAHN
AB			SUN PHARM INDs (IN)	EQ 250MG BASE	N62791 001	Jun 11, 1987	Jan	CAHN
AB				EQ 500MG BASE	N62791 002	Jun 11, 1987	Jan	CAHN
AB			YUNG SHIN PHARM	EQ 250MG BASE	N65152 001	Feb 24, 2005	Feb	NEWA
AB				EQ 500MG BASE	N65152 002	Feb 24, 2005	Feb	NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

+ UCB		EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML	N21369 001	Jun 21, 2004	Mar	CAHN
-----------	--	---	------------	--------------	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUSSIONEX

+ UCB		EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001	Dec 31, 1987	Mar	CAHN
-----------	--	---	------------	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

>D>	BP		SANDOZ	10MG	N80439 001		Apr	CRLD
>A>	BP	+		10MG	N80439 001		Apr	CRLD
>D>	BP			100MG	N80439 004		Apr	CRLD
>A>	BP	+		100MG	N80439 004		Apr	CRLD
>D>			THORAZINE					
>D>	BP	+	GLAXOSMITHKLINE	10MG	N09149 002		Apr	DISC
>A>		@		10MG	N09149 002		Apr	DISC
>D>	BP			25MG	N09149 007		Apr	DISC
>A>		@		25MG	N09149 007		Apr	DISC
>D>	BP			50MG	N09149 013		Apr	DISC
>A>		@		50MG	N09149 013		Apr	DISC

TABLET; ORAL

>D>	THORAZINE					
>D>	BP + GLAXOSMITHKLINE	100MG	N09149 018	Apr	DISC	
>A>	@	100MG	N09149 018	Apr	DISC	
>D>	BB	200MG	N09149 020	Apr	DISC	
>A>	@	200MG	N09149 020	Apr	DISC	

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	TEVA PHARMS	EQ 4GM RESIN/PACKET	N74554 001	Oct 02, 1996	Mar	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	N74554 002	Oct 02, 1996	Mar	CAHN
	CHOLESTYRAMINE LIGHT					
AB	TEVA PHARMS	EQ 4GM RESIN/PACKET	N74555 001	Sep 30, 1998	Mar	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	N74555 002	Sep 30, 1998	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	N76790 001	Apr 12, 2005	Mar	NEWA
----	------	-------	------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	COREPHARMA	50MG	N77150 001	Mar 11, 2005	Feb	NEWA
AB	IVAX PHARMS	100MG	N77020 002	Mar 01, 2005	Feb	NEWA
>A>	AB ROXANE	50MG	N77024 001	May 17, 2005	Apr	NEWA
>A>	AB	100MG	N77024 002	May 17, 2005	Apr	NEWA

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HCL

AA	TEVA PHARMS	EQ 300MG BASE/5ML	N74859 001	Jul 09, 1998	Mar	CAHN
----	-------------	-------------------	------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN

AT	HITECH PHARMA	EQ 0.3% BASE	N76673 001	Jan 21, 2005	Jan	NEWA
	TABLET; ORAL					
	CIPROFLOXACIN					
AB	COBALT	EQ 100MG BASE	N76794 001	Feb 10, 2005	Jan	NEWA
AB	SANDOZ	EQ 100MG BASE	N75939 001	Mar 03, 2005	Feb	NEWA
AB	TARO	EQ 100MG BASE	N76912 001	Feb 18, 2005	Jan	NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>A>	AB AKYMA PHARMS	EQ 10MG BASE	N77045 003	Apr 29, 2005	Apr	NEWA
>A>	AB	EQ 20MG BASE	N77045 002	Apr 29, 2005	Apr	NEWA
>A>	AB	EQ 40MG BASE	N77045 001	Apr 29, 2005	Apr	NEWA
AB	MYLAN	EQ 10MG BASE	N77039 001	Feb 03, 2005	Jan	NEWA
AB		EQ 20MG BASE	N77039 002	Feb 03, 2005	Jan	NEWA
AB		EQ 40MG BASE	N77039 003	Feb 03, 2005	Jan	NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

RANBAXY

1GM

N65210 001 Jan 26, 2005 Jan NEWA

>A> AB TEVA 500MG

N65154 001 May 18, 2005 Apr NEWA

TABLET; ORAL

CLARITHROMYCIN

AB GENPHARM 250MG

N65195 001 Mar 11, 2005 Feb NEWA

AB 500MG

N65195 002 Mar 11, 2005 Feb NEWA

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA TEVA PHARMS EQ 0.5MG BASE/5ML

N73095 001 Apr 21, 1992 Mar CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB ZYDUS PHARMS USA EQ 75MG BASE

N65217 001 Jan 31, 2005 Jan NEWA

AB EQ 150MG BASE

N65217 002 Jan 31, 2005 Jan NEWA

AB EQ 300MG BASE

N65217 003 Jan 31, 2005 Jan NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP HOSPIRA EQ 150MG BASE/ML

N62943 001 Sep 29, 1988 Mar CMFD

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1 TEVA PHARMS 0.05%

N74087 001 Feb 16, 1994 Mar CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB TEVA PHARMS 0.05%

N74089 001 Feb 16, 1994 Mar CAHN

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>A> AB KALI LABS 0.5MG

N77147 001 May 02, 2005 Apr NEWA

>A> AB 1MG

N77147 002 May 02, 2005 Apr NEWA

>A> AB 2MG

N77147 003 May 02, 2005 Apr NEWA

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

+ TARO 1%

N72640 001 Aug 31, 1993 Feb CRLD

LOTTRIMIN

@ SCHERING PLOUGH 1%

N17619 001 Feb DISC

MYCELEX

@ BAYER PHARMS 1%

N18183 001 Feb DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>A> IVAX PHARMS 50MG

N74949 004 Apr 25, 2005 Apr NEWA

TABLET; ORAL

CLOZAPINE

>A> AB	TEVA	25MG	N75162 001 Apr 26, 2005 Apr NEWA
>A> AB		100MG	N75162 002 Apr 26, 2005 Apr NEWA

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL

GASTROCROM

+ UCB	100MG/5ML	N20479 001 Feb 29, 1996 Mar CAHN
-------	-----------	----------------------------------

CYANOCOBALAMIN

SPRAY, METERED; NASAL

NASCOBAL

+ NASTECH PHARM	0.5MG/SPRAY	N21642 001 Jan 31, 2005 Jan NEWA
+ QUESTCOR PHARMS	0.5MG/SPRAY	N21642 001 Jan 31, 2005 Feb CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1 IVAX PHARMS	25MG	N65110 003 Mar 29, 2005 Mar NEWA
AB1	50MG	N65110 001 Mar 29, 2005 Mar NEWA
AB1	100MG	N65110 002 Mar 29, 2005 Mar NEWA
GENGRAF		
AB1 ABBOTT	50MG	N65003 002 May 12, 2000 Mar CTEC
SOLUTION; ORAL		
CYCLOSPORINE		
AB1 IVAX PHARMS	100MG/ML	N65078 001 Mar 25, 2005 Mar NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

@ ABC HOLDING

4MG

N88212 001 May 26, 1983 Feb DISC

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

+ PHARMACIA AND UPJOHN	7,500 IU/0.3ML	N20287 005 Apr 04, 2002 Jan NEWA
@	7,500 IU/0.75ML	N20287 008 Apr 04, 2002 Apr DISC
+ +	95,000IU/3.8ML(25,000IU/ML)	N20287 006 Apr 04, 2002 Apr NEWA
+ +	95,000IU/9.5ML(10,000IU/ML)	N20287 007 Apr 04, 2002 Apr NEWA

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

AB PROCTER AND GAMBLE	25MG	N17443 001 Feb CFTG
AB	50MG	N17443 003 Feb CFTG
AB +	100MG	N17443 002 Feb CFTG
DANTROLENE SODIUM		
AB IMPAX LABS	25MG	N76856 001 Mar 01, 2005 Feb NEWA
AB	50MG	N76856 002 Mar 01, 2005 Feb NEWA
AB	100MG	N76856 003 Mar 01, 2005 Feb NEWA

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+ CANYON

15MG/VIAL

N21271 001 Apr 04, 2003 Mar CAIN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
 CLARINEX D 24 HOUR
 + SCHERING 5MG;240MG

N21605 001 Mar 03, 2005 Mar NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)
 AB APOTEX 0.01MG/SPRAY

N76703 001 Jan 27, 2005 Jan NEWA

DESONIDE

CREAM; TOPICAL
 DESONIDE
 AB TEVA PHARMS 0.05%

N74027 001 Sep 28, 1992 Mar CAHN

DEXAMETHASONE

TABLET; ORAL
 DEXAMETHASONE
 PAR PHARM 0.25MG
 BP ROXANE 1.5MG

N88149 001 Apr 28, 1983 Mar CRLD

N84610 001 Mar CRLD

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 DEXAMETHASONE SODIUM PHOSPHATE
 >A> AP AM PHARM EQ 10MG PHOSPHATE/ML

N40572 001 Apr 22, 2005 Apr NEWA

DEXTROSE

INJECTABLE; INJECTION
 DEXTROSE 50% IN PLASTIC CONTAINER
 AP HOSPIRA 500MG/ML

N19445 001 Jun 03, 1986 Mar CMFD

DIAZEPAM

GEL; RECTAL
 DIASTAT
 >A> VALEANT 2.5MG/0.5ML
 >A> 5MG/ML
 >A> 10MG/2ML
 >A> 15MG/3ML
 >A> + 20MG/4ML
 >D> XCEL PHARMS 2.5MG/0.5ML
 >D> 5MG/ML
 >D> 10MG/2ML
 >D> 15MG/3ML
 >D> + 20MG/4ML

N20648 001 Jul 29, 1997 Apr CAHN

N20648 002 Jul 29, 1997 Apr CAHN

N20648 003 Jul 29, 1997 Apr CAHN

N20648 004 Jul 29, 1997 Apr CAHN

N20648 005 Jul 29, 1997 Apr CAHN

N20648 001 Jul 29, 1997 Apr CAHN

N20648 002 Jul 29, 1997 Apr CAHN

N20648 003 Jul 29, 1997 Apr CAHN

N20648 004 Jul 29, 1997 Apr CAHN

N20648 005 Jul 29, 1997 Apr CAHN

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
 DICLOFENAC SODIUM
 AB TEVA PHARMS 25MG
 AB 50MG
 AB 75MG

N74459 001 Jun 25, 1997 Mar CAHN

N74459 002 Jun 25, 1997 Mar CAHN

N74459 003 Jun 25, 1997 Mar CAHN

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL					
BENTYL					
AA + AXCAN SCANDIPHARM	10MG/5ML		N07961	002	Oct 15, 1984 Mar CTEC
DICYCLOMINE HCL					
AA MIKART	10MG/5ML		N40169	001	Mar 24, 2005 Mar NEWA

DIETHYLPROMION HYDROCHLORIDE

TABLET; ORAL					
DIETHYLPROMION HCL					
@ ABC HOLDING	25MG		N88267	001	Aug 25, 1983 Feb DISC
@	25MG		N88268	001	Aug 25, 1983 Feb DISC
TENUATE					
+ AVENTIS PHARMS	25MG		N11722	002	Feb CTEC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION					
D.H.E. 45					
>A> AP + VALEANT	1MG/ML		N05929	001	Apr CAHN
>D> AP + XCEL PHARMS	1MG/ML		N05929	001	Apr CAHN
SPRAY, METERED; NASAL					
MIGRAL					
>A> + VALEANT	0.5MG/INH		N20148	001	Dec 08, 1997 Apr CAHN
>D> + XCEL PHARM	0.5MG/INH		N20148	001	Dec 08, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION					
CARDIZEM					
AP + BIOVAIL LABS INTL	5MG/ML		N20027	001	Oct 24, 1991 Mar CAHN
+ 25MG/VIAL			N20027	003	Aug 18, 1995 Mar CAHN
TABLET, EXTENDED RELEASE; ORAL					
CARDIZEM LA					
BIOVAIL LABS INTL	120MG		N21392	001	Feb 06, 2003 Mar CAHN
	180MG		N21392	002	Feb 06, 2003 Mar CAHN
	240MG		N21392	003	Feb 06, 2003 Mar CAHN
	300MG		N21392	004	Feb 06, 2003 Mar CAHN
	360MG		N21392	005	Feb 06, 2003 Mar CAHN
+	420MG		N21392	006	Feb 06, 2003 Mar CAHN
TABLET; ORAL					
CARDIZEM					
AB BIOVAIL LABS INTL	30MG		N18602	001	Nov 05, 1982 Mar CAHN
AB	60MG		N18602	002	Nov 05, 1982 Mar CAHN
AB	90MG		N18602	003	Dec 08, 1986 Mar CAHN
AB +	120MG		N18602	004	Dec 08, 1986 Mar CAHN
DILTIAZEM HCL					
AB TEVA PHARMS	30MG		N74067	001	Nov 05, 1992 Mar CAHN
AB	60MG		N74067	002	Nov 05, 1992 Mar CAHN
AB	90MG		N74067	003	Nov 05, 1992 Mar CAHN
AB	120MG		N74067	004	Nov 05, 1992 Mar CAHN

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL					
CARDURA XL					
PFIZER	EQ 4MG BASE		N21269	001	Feb 22, 2005 Feb NEWA
+	EQ 8MG BASE		N21269	002	Feb 22, 2005 Feb NEWA

DOXEPEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPEPIN HCL
AA TEVA PHARMS EQ 10MG BASE/ML N71609 001 Nov 09, 1987 Mar CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE
AB PAR PHARM EQ 75MG BASE N65055 004 Apr 18, 2005 Mar NEWA
AB RANBAXY EQ 75MG BASE N65053 003 Sep 10, 2003 Mar CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
>A> + WEST WARD EQ 20MG BASE N65103 001 May 13, 2005 Apr NEWA
TABLET; ORAL
DOXYCYCLINE HYCLATE
>A> AB COREPHARMA EQ 20MG BASE N65182 001 May 13, 2005 Apr NEWA
>A> AB IVAX PHARMS EQ 20MG BASE N65163 001 May 13, 2005 Apr NEWA
>A> AB MUTUAL PHARMA EQ 20MG BASE N65134 001 May 13, 2005 Apr NEWA
PERIOSTAT
>D> + COLLAGENEX PHARMS 20MG N50783 001 Feb 02, 2001 Apr CFTG
>A> AB + EQ 20MG BASE N50783 001 Feb 02, 2001 Apr CFTG

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE
@ APOTHECON 2.5MG N75583 001 Aug 22, 2000 Feb DISC
@ 5MG N75583 002 Aug 22, 2000 Feb DISC
@ 10MG N75583 003 Aug 22, 2000 Feb DISC
@ 20MG N75583 004 Aug 22, 2000 Feb DISC
VASOTEC
AB BIOVAIL LABS INTL 2.5MG N18998 005 Jul 26, 1988 Mar CAHN
AB 5MG N18998 001 Dec 24, 1985 Mar CAHN
AB 10MG N18998 002 Dec 24, 1985 Mar CAHN
AB + 20MG N18998 003 Dec 24, 1985 Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC
AB BIOVAIL LABS INTL 5MG;12.5MG N19221 003 Jul 12, 1995 Mar CAHN
AB + 10MG;25MG N19221 001 Oct 31, 1986 Mar CAHN

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC
AP + BIOVAIL LABS INTL 1.25MG/ML N19309 001 Feb 09, 1988 Mar CAHN

ENTECAVIR

SOLUTION; ORAL
BARACLUDE
+ BRISTOL MYERS SQUIBB 0.05MG/ML N21798 001 Mar 29, 2005 Mar NEWA
TABLET; ORAL
BARACLUDE
BRISTOL MYERS SQUIBB 0.5MG N21797 001 Mar 29, 2005 Mar NEWA

TABLET; ORAL

BARACLUDE

+ BRISTOL MYERS SQUIBB 1MG

N21797 002 Mar 29, 2005 Mar NEWA

EPINEPHRINE

INJECTABLE; IM-SC

TWINJECT 0.30

+ HOLLISTER STIER LABS EQ 0.3MG /DELIVERY

N20800 001 May 30, 2003 Feb CTNA

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYMAX

AT MERZ PHARMS 2%

N62508 002 Jul 11, 1985 Jan CAHN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

@ BARR

EQ 250MG BASE

N62162 002

Feb DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HCL

>A> AP AM PHARM 10MG/ML
>A> AP PHARMAFORCE 10MG/ML

N76573 001 May 02, 2005 Apr NEWA

N76474 001 May 02, 2005 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

ASTRAZENECA

EQ 20MG BASE

N21153 001 Feb 20, 2001 Jan CRLD

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

NEXIUM IV

+ ASTRAZENECA 20MG/VIAL
+ 40MG/VIAL

N21689 001 Mar 31, 2005 Mar NEWA

N21689 002 Mar 31, 2005 Mar NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

AB2 + BERLEX 0.025MG/24HR

N20375 004 Mar 05, 1999 Jan CFTG

AB2 + 0.075MG/24HR

N20375 003 Mar 23, 1998 Jan CFTG

ESCLIM

@ WOMEN FIRST HLTHCARE 0.025MG/24HR
@ 0.0375MG/24HR
@ 0.05MG/24HR
@ 0.075MG/24HR
@ 0.1MG/24HR

N20847 001 Aug 04, 1998 Jan DISC

N20847 002 Aug 04, 1998 Jan DISC

N20847 003 Aug 04, 1998 Jan DISC

N20847 004 Aug 04, 1998 Jan DISC

N20847 005 Aug 04, 1998 Jan DISC

ESTRADIOL

AB2 MYLAN TECHNOLOGIES 0.025MG/24HR

N75182 003 Jan 26, 2005 Jan NEWA

AB2 0.075MG/24HR

N75182 002 Jan 26, 2005 Jan NEWA

VIVELLE

@ NOVARTIS 0.025MG/24HR

N20323 005 Aug 16, 2000 Jan DISC

AB1 0.05MG/24HR

N20323 002 Oct 28, 1994 Jan CRLD

AB1 0.1MG/24HR

N20323 004 Oct 28, 1994 Jan CRLD

VIVELLE-DOT

BX + NOVARTIS 0.025MG/24HR

N20538 009 May 03, 2002 Jan CRLD

FILM, EXTENDED RELEASE; TRANSDERMAL
VIVELLE-DOT

BX	+	NOVARTIS	0.0375MG/24HR	N20538 005 Jan 08, 1999 Jan CRLD
AB1	+		0.05MG/24HR	N20538 006 Jan 08, 1999 Jan CRLD
BX	+		0.075MG/24HR	N20538 007 Jan 08, 1999 Jan CRLD
AB1	+		0.1MG/24HR	N20538 008 Jan 08, 1999 Jan CRLD

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

>A>		ESTRADIOL AND NORGESTIMATE		
>A>	AB	BARR	1MG,1MG;N/A,0.09MG	N76812 001 Apr 29, 2005 Apr NEWA
		PREFEST		
>D>	+	DURAMED	1MG,1MG;0.09MG,N/A	N21040 001 Oct 22, 1999 Apr CFTG
>A>	AB	+	1MG,1MG;N/A,0.09MG	N21040 001 Oct 22, 1999 Apr CFTG

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

	ENJUVIA			
@	DURAMED	0.3MG	N21443 001 Dec 20, 2004 Mar DISC	
@		0.45MG	N21443 002 Dec 20, 2004 Mar DISC	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001 Sep 24, 1991 Mar CTEC	
	NORTREL 7/7/7			
	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478 001 Aug 30, 2002 Mar CTEC	

TABLET; ORAL-28

	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042 001 Sep 24, 1991 Mar CTEC	
	ORTHO-NOVUM 10/11-28			
AB	+	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354 002 Jan 11, 1982 Mar CRLD
	ORTHO-NOVUM 7/14-28			
	@ ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N19004 002 Apr 04, 1984 Feb DISC	
	OVCON-35			
AB		WARNER CHILCOTT	0.035MG;0.4MG	N17716 001 Mar CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE			
>A>	AB	ANDRX PHARMS	0.03MG;1.5MG	N77075 001 Apr 28, 2005 Apr NEWA

ETHOSUXIMIDE

SYRUP; ORAL

	ETHOSUXIMIDE			
AA	TEVA PHARMS	250MG/5ML	N81306 001 Jul 30, 1993 Mar CAHN	

EXENATIDE SYNTHETIC

>A>		INJECTABLE; SUBCUTANEOUS		
>A>		BYETTA		
>A>	+	AMYLIN	300UGM/1.2ML(250UGM/ML)	N21773 001 Apr 28, 2005 Apr NEWA
>A>	+		600UGM/2.4ML(250UGM/ML)	N21773 002 Apr 28, 2005 Apr NEWA

FENOFIBRATE

TABLET; ORAL

>A>		FENOFIBRATE						
>A>	AB	TEVA	54MG	N76433	001	May 13, 2005	Apr	NEWA
>A>	AB		160MG	N76433	002	May 13, 2005	Apr	NEWA
		TRICOR						
>D>		ABBOTT	54MG	N21203	001	Sep 04, 2001	Apr	CFTG
>A>	AB		54MG	N21203	001	Sep 04, 2001	Apr	CFTG
>D>	+		160MG	N21203	003	Sep 04, 2001	Apr	CFTG
>A>	AB	+	160MG	N21203	003	Sep 04, 2001	Apr	CFTG

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE								
AP	SABEX	2002	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

>A>	AB	+	PEDINOL	EQ 300MG BASE	N17604	002		Apr	CAHN
>D>	AB	+	RANBAXY	EQ 300MG BASE	N17604	002		Apr	CAHN
			NALFON 200						
>A>	AB		PEDINOL	EQ 200MG BASE	N17604	003		Apr	CAHN
>D>	AB		RANBAXY	EQ 200MG BASE	N17604	003		Apr	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

AB	ALZA		100UGM/HR	N19813	001	Aug 07, 1990	Jan	CFTG
	DURAGESIC-12							
	ALZA		12.5UGM/HR	N19813	005	Feb 04, 2005	Feb	NEWA
	DURAGESIC-25							
AB	+	ALZA	25UGM/HR	N19813	004	Aug 07, 1990	Jan	CFTG
	DURAGESIC-50							
AB	ALZA		50UGM/HR	N19813	003	Aug 07, 1990	Jan	CFTG
	DURAGESIC-75							
AB	ALZA		75UGM/HR	N19813	002	Aug 07, 1990	Jan	CFTG
	FENTANYL							
AB	MYLAN TECHNOLOGIES		25UGM/HR	N76258	001	Jan 28, 2005	Jan	NEWA
AB			50UGM/HR	N76258	002	Jan 28, 2005	Jan	NEWA
AB			75UGM/HR	N76258	003	Jan 28, 2005	Jan	NEWA
AB			100UGM/HR	N76258	004	Jan 28, 2005	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR

AB	+	AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Mar	CFTG
		FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCL						
AB		BARR	60MG;120MG	N76236	001	Apr 14, 2005	Mar	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	APOTEX		200MG/100ML	N76888	001	Mar 25, 2005	Mar	NEWA
----	--------	--	-------------	--------	-----	--------------	-----	------

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP APOTEX 200MG/100ML N76889 001 Mar 25, 2005 Mar NEWA

FLUCYTOSINECAPSULE; ORALANCOBON

>D>	ICN	250MG	N17001 001	Apr	CAHN
>D>	+	500MG	N17001 002	Apr	CAHN
>A>	VALEANT	250MG	N17001 001	Apr	CAHN
>A>	+	500MG	N17001 002	Apr	CAHN

FLUMAZENILINJECTABLE; INJECTIONFLUMAZENIL

>A> AP	SABEX 2002	0.5MG/5ML (0.1MG/ML)	N77071 001	May 03, 2005	Apr	NEWA
>A> AP		1MG/10ML (0.1MG/ML)	N77071 002	May 03, 2005	Apr	NEWA

FLUOCINOLONE ACETONIDEIMPLANT; INTRAVITREALRETISSERT

>A>	+	BAUSCH AND LOMB	0.59MG	N21737 001	Apr 08, 2005	Apr	NEWA
-----	---	-----------------	--------	------------	--------------	-----	------

FLUOCINONIDECREAM; TOPICALVANOS+ MEDICIS

0.1%

N21758 001 Feb 11, 2005 Feb NEWA

SOLUTION; TOPICALFLUOCINONIDE

AT	TEVA PHARMS	0.05%	N72522 001	Sep 28, 1990	Mar	CAHN
----	-------------	-------	------------	--------------	-----	------

FLUOROURACILINJECTABLE; INJECTIONFLUOROURACIL

>D> AP	+	ICN PUERTO RICO	50MG/ML	N12209 001	Apr	CAHN
>A> AP	+	VALEANT	50MG/ML	N12209 001	Apr	CAHN

FLUOXETINE HYDROCHLORIDECAPSULE; ORALFLUOXETINE

>A> AB	BARR	EQ 40MG BASE	N76251 001	May 18, 2005	Apr	NEWA
--------	------	--------------	------------	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDECONCENTRATE; ORALFLUPHENAZINE HCL

AA	TEVA PHARMS	5MG/ML	N73058 001	Aug 30, 1991	Mar	CAHN
----	-------------	--------	------------	--------------	-----	------

ELIXIR; ORALFLUPHENAZINE HCL

AA	TEVA PHARMS	2.5MG/5ML	N81310 001	Apr 29, 1993	Mar	CAHN
----	-------------	-----------	------------	--------------	-----	------

FLUTICASONE PROPIONATEAEROSOL, METERED; INHALATIONFLOVENT

+	GLAXOSMITHKLINE	0.044MG/INH	N20548 001	Mar 27, 1996	Jan	CRLD
+		0.11MG/INH	N20548 002	Mar 27, 1996	Jan	CRLD

AEROSOL, METERED; INHALATION

FLOVENT HFA						
+ GLAXOSMITHKLINE	0.044MG/INH	N21433	003	May 14, 2004	Jan	CRLD
+ GLAXOSMITHKLINE	0.11MG/INH	N21433	002	May 14, 2004	Jan	CRLD
LOTION; TOPICAL						
CUTIVATE						
+ GLAXOSMITHKLINE	0.05%	N21152	001	Mar 31, 2005	Mar	NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS						
FOLLISTIM AQ						
+ ORGANON USA INC	150 IU/0.18ML	N21211	003	Feb 11, 2004	Feb	NEWA
+ GLAXOSMITHKLINE	300 IU/0.36ML	N21211	001	Mar 23, 2004	Jan	CPOT
+ GLAXOSMITHKLINE	600 IU/0.72ML	N21211	002	Mar 23, 2004	Jan	CPOT
+ GLAXOSMITHKLINE	900 IU/1.08ML	N21211	004	Feb 11, 2005	Feb	NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION						
VITRAVENE PRESERVATIVE FREE						
@ NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Feb	DISC

FOSINOPRIL SODIUM

TABLET; ORAL						
FOSINOPRIL SODIUM						
>A> AB APOTEX	10MG	N76906	001	May 17, 2005	Apr	NEWA
>A> AB	20MG	N76906	002	May 17, 2005	Apr	NEWA
>A> AB	40MG	N76906	003	May 17, 2005	Apr	NEWA
AB INVAGEN PHARMS	10MG	N77222	001	Apr 20, 2005	Mar	NEWA
AB	20MG	N77222	002	Apr 20, 2005	Mar	NEWA
AB	40MG	N77222	003	Apr 20, 2005	Mar	NEWA

FUROSEMIDE

INJECTABLE; INJECTION						
FUROSEMIDE						
AP + LUITPOLD	10MG/ML	N18579	001	Nov 30, 1983	Feb	CRLD
LASIX						
@ AVENTIS PHARMS	10MG/ML	N16363	001		Feb	DISC

GABAPENTIN

CAPSULE; ORAL						
GABAPENTIN						
AB APOTEX	100MG	N75360	001	Apr 06, 2005	Mar	NEWA
AB	300MG	N75360	002	Apr 06, 2005	Mar	NEWA
AB	400MG	N75360	003	Apr 06, 2005	Mar	NEWA
AB EON	100MG	N75539	001	Apr 06, 2005	Mar	NEWA
AB	300MG	N75539	002	Apr 06, 2005	Mar	NEWA
AB	400MG	N75539	003	Apr 06, 2005	Mar	NEWA
AB IVAX PHARMS	100MG	N75477	001	Mar 23, 2005	Mar	NEWA
AB	300MG	N75477	002	Mar 23, 2005	Mar	NEWA
AB	400MG	N75477	003	Mar 23, 2005	Mar	NEWA

TABLET; ORAL

GABAPENTIN						
>A> AB IVAX PHARMS	600MG	N76017	004	Apr 29, 2005	Apr	NEWA
>A> AB	800MG	N76017	005	Apr 29, 2005	Apr	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
REMINYL
+ JOHNSON AND JOHNSON EQ 8MG BASE
EQ 24MG BASE

N21615 001 Dec 22, 2004 Jan CRLD
N21615 003 Dec 22, 2004 Jan CRLD

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN
+ BRISTOL MYERS SQUIBB 400MG/40ML(10MG/ML)
TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ BRISTOL MYERS SQUIBB 200MG/100ML(2MG/ML)
+ 400MG/200ML(2MG/ML)

N21062 004 Dec 17, 1999 Mar CPOT
N21062 001 Dec 17, 1999 Mar CPOT
N21062 002 Dec 17, 1999 Mar CPOT

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLYBURIDE AND METFORMIN HCL
AB TEVA 1.25MG;250MG
AB 2.5MG;500MG
AB 5MG;500MG

N76821 001 Jan 27, 2005 Jan NEWA
N76821 002 Jan 27, 2005 Jan NEWA
N76821 003 Jan 27, 2005 Jan NEWA

GLCOPYRROLATE

TABLET; ORAL
GLCOPYRROLATE
>D> AB COREPHARMA 1MG N40568 001 Dec 22, 2004 Apr CTEC
>A> AA 1MG N40568 001 Dec 22, 2004 Apr CTEC
>D> AB 2MG N40568 002 Dec 22, 2004 Apr CTEC
>A> AA 2MG N40568 002 Dec 22, 2004 Apr CTEC

ROBINUL
>D> AB + FIRST HORIZON 1MG N12827 001 Apr CTEC
>A> AA + 1MG N12827 001 Apr CTEC

ROBINUL FORTE
>D> AB + FIRST HORIZON 2MG N12827 002 Apr CTEC
>A> AA + 2MG N12827 002 Apr CTEC

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN
@ WATSON LABS (UTAH) 2,000 UNITS/VIAL N17016 009 Dec 27, 1984 Feb CAHN
@ 2,000 UNITS/VIAL N17016 011 Feb 16, 1990 Feb CAHN
@ 5,000 UNITS/VIAL N17016 006 Feb CAHN
AP + 10,000 UNITS/VIAL N17016 007 Feb CAHN
@ 15,000 UNITS/VIAL N17016 010 Feb 15, 1985 Feb CAHN
@ 20,000 UNITS/VIAL N17016 004 Feb CAHN

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V
AB + J AND J 125MG/5ML N62483 001 Jan 26, 1984 Feb CFTG
GRISEOFULVIN
AB STIEFEL 125MG/5ML N65200 001 Mar 02, 2005 Feb NEWA

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

AB	TEVA PHARMS	EQ 4MG BASE	N74267 001 Jun 01, 1994 Mar CAHN
AB		EQ 8MG BASE	N74267 002 Jun 01, 1994 Mar CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA	+	TEVA PHARMS	EQ 2MG BASE/ML	N71617 001 Dec 01, 1988 Mar CAHN
----	---	-------------	----------------	----------------------------------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	IVAX PHARMS	1.5MG/5ML;5MG/5ML	N40285 001 Jul 19, 1999 Jan CAHN
----	-------------	-------------------	----------------------------------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

@	ABC HOLDING	10MG	N88846 001 Feb 26, 1985 Feb DISC
@		25MG	N88847 001 Feb 26, 1985 Feb DISC
@		50MG	N88848 001 Feb 26, 1985 Feb DISC
@		100MG	N88849 001 Feb 26, 1985 Feb DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	ABC HOLDING	25MG	N85683 001 Feb DISC
@		50MG	N83965 001 Feb DISC
@		50MG	N85672 001 Feb DISC
>D>	AB	IVAX PHARMS	N83177 002 Apr CRLD
>A>	AB	+	N83177 002 Apr CRLD
>D>	AB	+	N85022 001 Apr DISC
>A>		@	N85022 001 Apr DISC
		100MG	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI SYNTHELABO	12.5MG;300MG	N20758 003 Aug 31, 1998 Mar CRLD
+	25MG;300MG	N20758 004 Mar 15, 2005 Mar NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	MYLAN	12.5MG;EQ 10MG BASE	N77093 001 Mar 28, 2005 Mar NEWA
AB		12.5MG;EQ 20MG BASE	N77093 002 Mar 28, 2005 Mar NEWA
AB		25MG;EQ 20MG BASE	N77093 003 Mar 28, 2005 Mar NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS	12.5MG;160MG	N20818 002 Mar 06, 1998 Mar CRLD
+	25MG;160MG	N20818 003 Jan 17, 2002 Mar CRLD

HYDROCORTISONE

ENEMA; RECTAL
HYDROCORTISONE
AB TEVA PHARMS 100MG/60ML N74171 001 May 27, 1994 Mar CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE
AB TEVA PHARMS 0.2% N74489 001 Aug 12, 1998 Mar CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PALLADONE
PURDUE PHARMA LP 16MG N21044 002 Sep 24, 2004 Feb CRLD
+ 32MG N21044 004 Sep 24, 2004 Feb CRLD

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE
AB TEVA PHARMS 200MG N40081 001 Sep 30, 1994 Mar CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE
@ WATSON LABS 125MG/ML N17439 001 Mar CAHN
@ 250MG/ML N17439 002 Mar CAHN

IBANDRONATE SODIUM

TABLET; ORAL			
BONIVA			
+ ROCHE	EQ 2.5MG BASE	N21455 001	May 16, 2003 Feb CMFD
	EQ 150MG BASE	N21455 002	Mar 24, 2005 Apr CRLD
>D> >A> +	EQ 150MG BASE	N21455 002	Mar 24, 2005 Apr CRLD
	EQ 150MG BASE	N21455 002	Mar 24, 2005 Mar NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL
@ TEVA 10MG N83729 001 Feb DISC
@ 25MG N83729 004 Feb DISC
@ 50MG N83729 003 Feb DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION			
IPRATROPIUM BROMIDE			
>A> AN BREATH LTD	0.02%	N76291 001	May 09, 2005 Apr NEWA

IRON DEXTRAN

INJECTABLE; INJECTION			
INFED			
BP + WATSON LABS (UTAH)	EQ 50MG IRON/ML	N17441 001	Feb CAHN

IRON SUCROSE

INJECTABLE; INTRAVENOUS
VENOFER
+ LUITPOLD EQ 100MG BASE/5ML(EQ 20MG
BASE/ML) N21135 001 Nov 06, 2000 Mar CPOT
EQ 50MG BASE/2.5ML(EQ 20MG
BASE/ML) N21135 002 Mar 20, 2005 Mar NEWA
EQ 75MG BASE/3.75ML(EQ 20MG
BASE/ML) N21135 003 Mar 29, 2005 Mar NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE; ORAL
DYNACIRC CR
RELIANT PHARMS 5MG N20336 001 Jun 01, 1994 Mar CRLD

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
@ APOTHECON EQ 500MG BASE N62726 001 Mar 06, 1987 Feb DISC

KETOCONAZOLE

SHAMPOO; TOPICAL
KETOCONAZOLE
AB QLT USA 2% N76942 001 Apr 11, 2005 Mar NEWA

LACTULOSE

SOLUTION; ORAL
EVALOSE
AA TEVA PHARMS 10GM/15ML N73497 001 May 28, 1993 Mar CAHN
SOLUTION; ORAL, RECTAL
HEPTALAC
AA TEVA PHARMS 10GM/15ML N73504 001 May 28, 1993 Mar CAHN

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION
REFLUDAN
+ BERLEX 50MG/VIAL N20807 001 Mar 06, 1998 Mar CAIN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE
>D> AP BEDFORD EQ 10MG BASE/ML N40347 001 Apr 25, 2000 Apr CRLD
>A> AP + EQ 10MG BASE/ML N40347 001 Apr 25, 2000 Apr CRLD
>D> AP + HOSPIRA EQ 10MG BASE/ML N40147 001 Jun 25, 1997 Apr DISC
>A> @ EQ 10MG BASE/ML N40147 001 Jun 25, 1997 Apr DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS
ELIGARD
+ QLT USA 22.5MG/VIAL N21379 001 Jul 24, 2002 Jan CAHN

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION
XOPENEX HFA
+ SEPRACOR EQ 0.045MG BASE/INH N21730 001 Mar 11, 2005 Mar NEWA

LEVOFLOXACIN

TABLET; ORAL					
LEVAQUIN					
ORTHO MCNEIL PHARM	250MG	N20634	001	Dec 20,	1996 Mar CTEC
	500MG	N20634	002	Dec 20,	1996 Mar CTEC
AB +	750MG	N20634	003	Sep 08,	2000 Jan CFTG
LEVOFLOXACIN					
AB TEVA	750MG	N76361	003	Jan 26,	2005 Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL PRESERVATIVE FREE

>A> AP	AM PHARM	2%	N17584	001	Apr CAHN
>A> AP		4%	N17584	002	Apr CAHN
>D> AP	AM PHARM PARTNERS	2%	N17584	001	Apr CAHN
>D> AP		4%	N17584	002	Apr CAHN
JELLY; TOPICAL					
LIDOCAINE HCL					
AT	TEVA PHARMS	2%	N81318	001	Apr 29, 1993 Mar CAHN

LORAZEPAM

SOLUTION; ORAL

LORAZEPAM

ROXANE 0.5MG/5ML

N74648 001 Mar 18, 1997 Jan CMFD

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYRON

>D> +	BERTEK PHARMS	EQ 85MG BASE/GM	N16763	001	Apr CAHN
>A> +	MYLAN BERTEK	EQ 85MG BASE/GM	N16763	001	Apr CAHN

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

@ GE HEALTHCARE 37.9MG/ML

N20652 001 Nov 26, 1997 Jan DISC

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

AB TEVA PHARMS 100MG N73580 001 Jan 04, 1995 Mar CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL

@ ABC HOLDING 12.5MG

N85253 001 Feb DISC

@ 25MG

N85252 001 Feb DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB TEVA PHARMS 40MG/ML N75681 001 May 05, 2003 Mar CAHN

MEMANTINE HYDROCHLORIDE

>A> SOLUTION; ORAL
 >A> NAMENDA
 >A> + FOREST LABS 2MG/ML N21627 001 Apr 18, 2005 Apr NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
 SOLAGE
 + BARRIER 2%:0.01% N20922 001 Dec 10, 1999 Feb CAHN

METAPROTERENOL SULFATE

SYRUP; ORAL
 METAPROTERENOL SULFATE
 @ TEVA PHARMS 10MG/5ML N73034 001 Aug 30, 1991 Mar CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL					
METFORMIN HCL					
AB	ANDRX PHARMS	750MG	N76869	001	Apr 12, 2005 Mar NEWA
AB	PUREPAC PHARM	750MG	N76878	001	Apr 13, 2005 Mar NEWA
AB	TEVA	750MG	N76864	001	Apr 12, 2005 Mar NEWA
AB	ZYDUS PHARMS USA	500MG	N77060	001	Apr 20, 2005 Mar NEWA
>A> AB		750MG	N77078	001	Apr 21, 2005 Apr NEWA
TABLET; ORAL					
METFORMIN HCL					
AB	ZYDUS PHARMS USA	500MG	N77064	001	Apr 18, 2005 Mar NEWA
AB		850MG	N77064	002	Apr 18, 2005 Mar NEWA
AB		1GM	N77064	003	Apr 18, 2005 Mar NEWA

METHAZOLAMIDE

TABLET; ORAL					
METHAZOLAMIDE					
AB	TEVA PHARMS	25MG	N40001	001	Jun 30, 1993 Mar CAHN
AB		50MG	N40001	002	Jun 30, 1993 Mar CAHN

METHIMAZOLE

TABLET; ORAL					
METHIMAZOLE					
AB	CEDAR PHARMS	5MG	N40547	001	Feb 18, 2005 Jan NEWA
AB		10MG	N40547	002	Feb 18, 2005 Jan NEWA
AB		20MG	N40547	004	Feb 18, 2005 Jan NEWA
>D> AB	+ GENPHARM	20MG	N40350	003	Jun 07, 2001 Apr DISC
>A>	@	20MG	N40350	003	Jun 07, 2001 Apr DISC
AB	+	20MG	N40350	003	Jun 07, 2001 Jan CFTG

METHOTREXATE SODIUM

INJECTABLE; INJECTION					
METHOTREXATE					
>D> AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999 Apr DISC
>A>	@	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999 Apr DISC
>A> AP	+ MAYNE PHARMA USA	EQ 50MG BASE/2ML (25 MG/ML)	N11719	010	Dec 15, 2004 Apr NEWA
METHOTREXATE LPF					
>D> AP	+ MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719	007	Mar 31, 1982 Apr DISC
>A>	@	EQ 25MG BASE/ML	N11719	007	Mar 31, 1982 Apr DISC

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

>D>	AP	BIGMAR BIOPEN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Apr	DISC
>A>		@	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Apr	DISC
>D>	AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Apr	DISC
>A>		@	EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Apr	DISC
>A>	+	MAYNE PHARMA USA	EQ 20MG BASE/2ML (10 MG/ML)	N11719 014	Apr 13, 2005	Apr	NEWA
>A>	AP	+	EQ 500MG BASE/20ML (25 MG/ML)	N11719 013	Apr 13, 2005	Apr	NEWA
>A>	AP	+	ED 1GM BASE/40ML (25 MG/ML)	N11719 012	Apr 13, 2005	Apr	NEWA
>A>	AP	+	EQ 2.5GM BASE/100ML (25 MG/ML)	N11719 011	Apr 13, 2005	Apr	NEWA
			METHOTREXATE SODIUM				
>D>	AP	BEDFORD	EQ 25MG BASE/ML	N89340 001	Sep 16, 1986	Apr	CPOT
>A>	AP		EQ 50 MG BASE/2ML (25 ML/ML)	N89340 001	Sep 16, 1986	Apr	CPOT
>D>	AP		EQ 25MG BASE/ML	N89341 001	Sep 16, 1986	Apr	CPOT
>A>	AP		EQ 100MG BASE/4ML (25 MG/ML)	N89341 001	Sep 16, 1986	Apr	CPOT
>D>	AP		EQ 25MG BASE/ML	N89342 001	Sep 16, 1986	Apr	CPOT
>A>	AP		EQ 200MG BASE/8ML (25 MG/ML)	N89342 001	Sep 16, 1986	Apr	CPOT
>D>	AP		EQ 25MG BASE/ML	N89343 001	Sep 16, 1986	Apr	CPOT
>A>	AP		EQ 250MG BASE/10ML (25 MG/ML)	N89343 001	Sep 16, 1986	Apr	CPOT
		@ MAYNE PHARMA USA	EQ 20MG BASE/VIAL	N11719 001		Mar	DISC
>D>	AP	+	EQ 25MG BASE/ML	N11719 005		Apr	DISC
>A>		@	EQ 25MG BASE/ML	N11719 005		Apr	DISC
>D>	AP	NORBROOK	EQ 25MG BASE/ML	N88648 001	May 09, 1986	Apr	DISC
>A>		@	EQ 25MG BASE/ML	N88648 001	May 09, 1986	Apr	DISC
>D>	AP	PHARMACHEMIE USA	EQ 25MG BASE/ML	N89158 001	Jul 08, 1988	Apr	DISC
>A>		@	EQ 25MG BASE/ML	N89158 001	Jul 08, 1988	Apr	DISC
		MEXATE-AQ					
>D>	AP	BRISTOL MYERS	EQ 25MG BASE/ML	N88760 001	Feb 14, 1985	Apr	DISC
>A>		@	EQ 25MG BASE/ML	N88760 001	Feb 14, 1985	Apr	DISC

METHYLDOPA

TABLET; ORAL

ALDOMET

@ MERCK

500MG

N13400 002

Jan DISC

METHYLDOPA

AB + MYLAN

500MG

N70076 001

Apr 18, 1985 Jan CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

@ MERCK

50MG/ML

N13401 001

Jan DISC

METHYLDOPATE HCL

AP + LUITPOLD

50MG/ML

N71279 001

Oct 02, 1987 Jan CRLD

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHSERGINE

+ NOVARTIS

0.2MG

N06035 003

Jan CRLD

METHYL PREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

AB + PHARMACIA AND UPJOHN

40MG/ML

N11757 001

Feb CFTG

AB +

80MG/ML

N11757 004

Feb CFTG

METHYL PREDNISOLONE ACETATE

AB SICOR PHARMS

40MG/ML

N40557 001

Feb NEWA

AB

80MG/ML

N40557 002

Feb NEWA

METOLAZONE

TABLET; ORAL	ZAROXOLYN				
AB UCB	2.5MG	N17386 001	Mar	CAHN	
AB +	5MG	N17386 002	Mar	CAHN	
AB +	10MG	N17386 003	Mar	CAHN	

METOPROLOL TARTRATE

TABLET; ORAL	METOPROLOL TARTRATE				
AB TEVA PHARMS	50MG	N74333 001	Jan 27, 1994	Mar	CAHN
AB	100MG	N74333 002	Jan 27, 1994	Mar	CAHN

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)	MYCAMINE				
+ ASTELLAS	50MG/VIAL	N21506 002	Mar 16, 2005	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION	MIDAZOLAM HCL				
AP HOSPIRA	EQ 1MG BASE/ML	N75293 001	Jun 20, 2000	Mar	CMFD
AP	EQ 5MG BASE/ML	N75293 002	Jun 20, 2000	Mar	CMFD
AP INTL MEDICATED	EQ 1MG BASE/ML	N76144 001	Jan 26, 2005	Jan	NEWA
AP	EQ 5MG BASE/ML	N76144 002	Jan 26, 2005	Jan	NEWA
SYRUP; ORAL	MIDAZOLAM HCL				
>A> AA PADDOCK	EQ 2MG BASE/ML	N76379 001	May 02, 2005	Apr	NEWA

MOMETASONE FUROATE

CREAM; TOPICAL	ELOCON				
AB + SCHERING	0.1%	N19625 001	May 06, 1987	Jan	CFTG
MOMETASONE FUROATE					
AB ALTANA	0.1%	N76171 001	Apr 08, 2005	Mar	NEWA
AB TARO	0.1%	N76679 001	Dec 21, 2004	Jan	NEWA
LOTION; TOPICAL	ELOCON				
AB + SCHERING	0.1%	N19796 001	Mar 30, 1989	Mar	CFTG
MOMETASONE FUROATE					
AB AGIS INDS	0.1%	N77180 001	Apr 06, 2005	Mar	NEWA
OINTMENT; TOPICAL	MOMETASONE FUROATE				
AB ALTANA	0.1%	N77061 001	Mar 28, 2005	Mar	NEWA
POWDER; INHALATION	ASMANEX TWISTHALER				
+ SCHERING	0.22MG/INH	N21067 001	Mar 30, 2005	Mar	NEWA

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL	NASONEX				
>A> + SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N20762 001	Oct 01, 1997	Apr	CAHN
>D> + SHIRE	EQ 0.05MG BASE/SPRAY	N20762 001	Oct 01, 1997	Apr	CAHN
+ SCHERING	EQ 0.05MG BASE/SPRAY	N20762 001	Oct 01, 1997	Mar	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX	LIGAND	30MG	N21260	001	Mar 20, 2002	Mar	CRLD
BX		60MG	N21260	002	Mar 20, 2002	Mar	CRLD
		90MG	N21260	003	Mar 20, 2002	Mar	CRLD
	KADIAN						
	ALPHARMA US PHARMS	20MG	N20616	001	Jul 03, 1996	Mar	CRLD
BX		30MG	N20616	004	Mar 09, 2001	Mar	CRLD
		50MG	N20616	002	Jul 03, 1996	Mar	CRLD
BX		60MG	N20616	005	Mar 09, 2001	Mar	CRLD

NADOLOL

TABLET; ORAL

NADOLOL

AB	TEVA PHARMS	80MG	N74368	001	Aug 31, 1994	Mar	CAHN
AB		120MG	N74368	002	Aug 31, 1994	Mar	CAHN
AB		160MG	N74368	003	Aug 31, 1994	Mar	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP	HOSPIRA	0 . 4MG/ML	N70172	001	Sep 24, 1986	Mar	CMFD
----	---------	------------	--------	-----	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

>A>	AB	PERRIGO R AND D	250MG	N77339	001	Apr 27, 2005	Apr	NEWA
>A>	AB		375MG	N77339	002	Apr 27, 2005	Apr	NEWA
>A>	AB		500MG	N77339	003	Apr 27, 2005	Apr	NEWA
	AB	TEVA PHARMS	250MG	N74207	001	Dec 21, 1993	Mar	CAHN
	AB		375MG	N74207	002	Dec 21, 1993	Mar	CAHN
	AB		500MG	N74207	003	Dec 21, 1993	Mar	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	TEVA PHARMS	EQ 250MG BASE	N74289	001	Jan 27, 1994	Mar	CAHN
AB		EQ 500MG BASE	N74289	002	Jan 27, 1994	Mar	CAHN

NESIRITIDE

FOR SOLUTION; INTRAVENOUS

NATRECOR

>D>	+ SCIOS	1 . 5MG/VIAL	N20920	001	Aug 10, 2001	Apr	CAIN
-----	---------	--------------	--------	-----	--------------	-----	------

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

>A>	+ SCIOS	1 . 5MG/VIAL	N20920	001	Aug 10, 2001	Apr	CAIN
-----	---------	--------------	--------	-----	--------------	-----	------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

>A>	BARR	500MG	N76378	001	Apr 26, 2005	Apr	NEWA
>A>	AB	750MG	N76378	002	Apr 26, 2005	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

>A>	NIACIN					
AB	BARR	1GM	N76250	001	Apr 14, 2005	Mar NEWA
	NIASPAN					
>D>	+ KOS	500MG	N20381	002	Jul 28, 1997	Apr CFTG
>A>	AB +	500MG	N20381	002	Jul 28, 1997	Apr CFTG
>D>	+ 750MG		N20381	003	Jul 28, 1997	Apr CFTG
>A>	AB +	750MG	N20381	003	Jul 28, 1997	Apr CFTG
AB	+ 1GM		N20381	004	Jul 28, 1997	Mar CFTG

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

+ ESP PHARMA 2.5MG/ML

N19734 001 Jan 30, 1992 Mar CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	EON	75MG;25MG	N77066	001	Apr 05, 2005	Mar NEWA
AB	RANBAXY	75MG;25MG	N76951	001	Mar 30, 2005	Mar NEWA

NYSTATIN

POWDER; TOPICAL

NYSTATIN

>A>	AT UPSHER SMITH	100,000 UNITS/GM	N65183	001	May 03, 2005	Apr NEWA
-----	-----------------	------------------	--------	-----	--------------	----------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	BEDFORD	EQ 0.2MG BASE/ML	N76330	001	Apr 08, 2005	Mar NEWA
AP		EQ 1MG BASE/ML	N76330	002	Apr 08, 2005	Mar NEWA
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
AP	BEDFORD	EQ 0.05MG BASE/ML	N76313	001	Mar 28, 2005	Mar NEWA
AP		EQ 0.1MG BASE/ML	N76313	003	Mar 28, 2005	Mar NEWA
AP		EQ 0.5MG BASE/ML	N76313	002	Mar 28, 2005	Mar NEWA
	SANDOSTATIN					
AP	+ NOVARTIS	EQ 0.05MG BASE/ML	N19667	001	Oct 21, 1988	Mar CFTG
AP	+ 0.1MG BASE/ML		N19667	002	Oct 21, 1988	Mar CFTG
AP	+ 0.2MG BASE/ML		N19667	004	Jun 12, 1991	Mar CFTG
AP	+ 0.5MG BASE/ML		N19667	003	Oct 21, 1988	Mar CFTG
AP	+ 1MG BASE/ML		N19667	005	Jun 12, 1991	Mar CFTG

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ UCB 250MG

N19715 001 Jul 31, 1990 Mar CAHN

OMEПRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

>D>	ASTRAZENECA	40MG	N19810	002	Jan 15, 1998	Apr CRLD
>A>	+ 40MG		N19810	002	Jan 15, 1998	Apr CRLD
	40MG		N19810	002	Jan 15, 1998	Mar CTEC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

+ SANOFI	50MG/VIAL	N21492 001	Aug 09, 2002	Mar	CRLD
+ SANOFI SYNTHELABO	50MG/10ML (5MG/ML)	N21759 001	Jan 31, 2005	Jan	NEWA
+	100MG/20ML (5MG/ML)	N21759 002	Jan 31, 2005	Jan	NEWA

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

>D> AB	IVAX PHARMS	30MG	N70945 001	Aug 03, 1987	Apr	CRLD
>A> AB	+	30MG	N70945 001	Aug 03, 1987	Apr	CRLD
>D>	SERAX					
>D> AB	ALPHARMA US PHARMS	10MG	N15539 002		Apr	DISC
>A>	@	10MG	N15539 002		Apr	DISC
>D> AB		15MG	N15539 004		Apr	DISC
>A>	@	15MG	N15539 004		Apr	DISC
>D> AB	+	30MG	N15539 006		Apr	DISC
>A>	@	30MG	N15539 006		Apr	DISC

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+ AM BIOSCIENCE	100MG/VIAL	N21660 001	Jan 07, 2005	Jan	NEWA
-----------------	------------	------------	--------------	-----	------

PEMOLINE

TABLET, CHEWABLE; ORAL

PEMOLINE

AB	TEVA PHARMS	37.5MG	N75555 001	Feb 18, 2000	Mar	CAHN
	TABLET; ORAL					
	PEMOLINE					
AB	TEVA PHARMS	18.75MG	N75030 003	Feb 22, 2000	Mar	CAHN

AB		37.5MG	N75030 001	Jan 29, 1999	Mar	CAHN
AB		75MG	N75030 002	Jan 29, 1999	Mar	CAHN

PENTOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM PENTOBARBITAL

@ VALEANT PHARM INTL

100MG

N83264 001

Jan DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

BONTRIL PDM

AA	+	VALEANT	35MG	N85272 001	Feb	CRLD	
		CAM-METRAZINE					
		@ ABC HOLDING	35MG	N83922 001	Feb	DISC	
		@	35MG	N85318 001	Feb	DISC	
		@	35MG	N85320 001	Feb	DISC	
		@	35MG	N85321 001	Feb	DISC	
		@	35MG	N85511 001	Feb	DISC	
		@ CAMALL	35MG	N85756 001	Feb	DISC	
		PHENDIMETRAZINE TARTRATE					
		@ ABC HOLDING	35MG	N85761 001	Feb	DISC	
		@	35MG	N85941 001	Jun 27, 1983	Feb	DISC
		@ EON	35MG	N85830 001		Feb	DISC

TABLET; ORAL

X-TROZINE

@ SHIRE RICHWOOD	35MG	N86553 001	Feb	DISC
@	35MG	N86554 001	Feb	DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ONA-MAST

@ MAST MM	30MG	N86511 001	Feb	DISC
@	30MG	N86516 001	Feb	DISC

PHENTERMINE HCL

@ ABC HOLDING	18.75MG	N88576 001	May 23, 1984	Feb	DISC
@	30MG	N85417 001		Feb	DISC
@	30MG	N86732 002		Feb	DISC
@	30MG	N87215 001		Feb	DISC
@	37.5MG	N87915 001	Dec 22, 1983	Feb	DISC
@	37.5MG	N87918 001	Dec 22, 1983	Feb	DISC
@	37.5MG	N87930 001	Oct 14, 1983	Feb	DISC
@	37.5MG	N88610 001	Jun 04, 1984	Feb	DISC
@	37.5MG	N88611 001	Jun 04, 1984	Feb	DISC
@	37.5MG	N88625 001	Aug 23, 1984	Feb	DISC
@ CAMALL	15MG	N86735 001		Feb	DISC
@	30MG	N87226 001		Feb	DISC

TABLET; ORAL

ONA MAST

@ MAST MM	8MG	N86260 001	Feb	DISC
-----------	-----	------------	-----	------

PHENTERMINE HCL

@ ABC HOLDING	8MG	N83923 001	Feb	DISC	
@	8MG	N85319 001	Feb	DISC	
@	37.5MG	N87805 001	Dec 06, 1982	Feb	DISC
@	37.5MG	N88596 001	Apr 04, 1984	Feb	DISC

AA LANNETT	37.5MG	N40555 001	Apr 15, 2005	Mar	NEWA
------------	--------	------------	--------------	-----	------

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB	EQ 15MG BASE	N11613 004	Mar	CAHN
+	EQ 30MG BASE	N11613 002	Mar	CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN

AP + ELKINS SINN	50MG/ML	N84307 001	Mar	CTEC
------------------	---------	------------	-----	------

PHENYTOIN SODIUM

AP HOSPIRA	50MG/ML	N89521 001	Mar 17, 1987	Mar	CMFD
------------	---------	------------	--------------	-----	------

AP	50MG/ML	N89744 001	Dec 18, 1987	Mar	CMFD
----	---------	------------	--------------	-----	------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB TEVA PHARMS	10MG	N74103 001	Aug 28, 1992	Mar	CAHN
AB	20MG	N74103 002	Aug 28, 1992	Mar	CAHN

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	HOSPIRA	14.9MG/ML	N20161 005	Nov 30, 1992	Mar	CMFD
AP		745MG/100ML	N20161 001	Nov 30, 1992	Mar	CMFD
	POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER					
AP	HOSPIRA	1.49GM/100ML	N20161 002	Nov 30, 1992	Mar	CMFD

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

UROCIT-K

MISSION PHARMA

5MEQ

+

10MEQ

N19071 001 Aug 30, 1985 Jan CTNA
N19071 002 Aug 31, 1992 Jan CTNAPRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

+ AMYLIN

EQ 3MG BASE/5ML (EQ 0.6MG
BASE/ML)

N21332 001 Mar 16, 2005 Mar NEWA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	IVAX PHARMS	15MG/5ML	N40287 001	May 28, 1999	Jan	CAHN
AA	TEVA PHARMS	15MG/5ML	N40322 001	Jan 19, 2000	Mar	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAFRED

AA	+ UCB	EQ 5MG BASE/5ML	N19157 001	May 28, 1986	Mar	CAHN
>A>	AA PHARM ASSOC	EQ 15MG BASE/5ML	N76913 001	Apr 25, 2005	Apr	NEWA

PRIMIDONE

TABLET; ORAL

MYSOLINE

>A>	AB + VALEANT	50MG	N09170 003		Apr	CAHN
>A>	AB	250MG	N09170 002		Apr	CAHN
>D>	AB + XCEL PHARMS	50MG	N09170 003		Apr	CAHN
>D>	AB	250MG	N09170 002		Apr	CAHN

PRIMIDONE

AB	VINTAGE PHARMS	50MG	N40586 001	Feb 24, 2005	Feb	NEWA
AB		250MG	N40586 002	Feb 24, 2005	Feb	NEWA

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB	TEVA PHARMS	EQ 5MG BASE	N40120 001	Jul 11, 1996	Mar	CAHN
AB		EQ 10MG BASE	N40120 002	Jul 11, 1996	Mar	CAHN

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

AO	+ WATSON LABS (UTAH)	50MG/ML	N17362 002		Feb	CAHN
----	----------------------	---------	------------	--	-----	------

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
 PROMETHAZINE HCL
 ABLE 12.5MG N40558 001 Jul 01, 2004 Jan CTEC

PROPOFOL

INJECTABLE; INJECTION
 PROPOFOL
 AB BEDFORD 10MG/ML N74848 001 Apr 19, 2005 Mar NEWA

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
 INDERAL
 >D> AB + WYETH PHARMS INC 10MG N16418 001 Apr CRLD
 >A> AB 10MG N16418 001 Apr CRLD

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
 QUINAPRIL HCL
 AB EON EQ 5MG BASE N76803 001 Mar 02, 2005 Feb NEWA
 AB EQ 10MG BASE N76803 002 Mar 02, 2005 Feb NEWA
 AB EQ 20MG BASE N76803 003 Mar 02, 2005 Feb NEWA
 AB EQ 40MG BASE N76803 004 Mar 02, 2005 Feb NEWA
 AB PAR PHARM EQ 5MG BASE N76036 001 Jan 28, 2005 Jan NEWA
 AB EQ 10MG BASE N76036 002 Jan 28, 2005 Jan NEWA
 AB EQ 20MG BASE N76036 003 Jan 28, 2005 Jan NEWA
 AB EQ 40MG BASE N76036 004 Jan 28, 2005 Jan NEWA

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
 QUINIDINE SULFATE
 + TEVA PHARMS 300MG N40045 001 Jun 30, 1994 Mar CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 RANITIDINE HCL
 AP BEN VENUE EQ 25MG BASE/ML N74777 001 Mar 02, 2005 Feb NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)
 AMMONUL
 + UCYCLYD 10%;10% (5GM/50ML;5GM/50ML) N20645 001 Feb 17, 2005 Feb NEWA

SODIUM CHLORIDE

SOLUTION; IRRIGATION
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AT HOSPIRA 450MG/100ML N18380 001 Mar CMFD

SOMATREM

INJECTABLE; INJECTION
 PROTROPIN
 @ GENENTECH 5MG/VIAL N19107 001 Oct 17, 1985 Mar DISC
 @ 10MG/VIAL N19107 002 Oct 24, 1989 Mar DISC

SOMATROPIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
 SEROSTIM LQ
 SERONO 6MG/0.05VIAL N20604 005 Feb 11, 2005 Feb NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
 SULFAMETHOXAZOLE AND TRIMETHOPRIM
 AB INTERPHARM 400MG;80MG N76899 001 Jan 27, 2005 Jan NEWA
 AB 800MG;160MG N76899 002 Jan 27, 2005 Jan NEWA

TACROLIMUS

CAPSULE; ORAL
 PROGRAF
 + FUJISAWA HLTHCARE EQ 1MG BASE N50708 001 Apr 08, 1994 Jan CRLD

TAMOXIFEN CITRATE

TABLET; ORAL
 TAMOXIFEN CITRATE
 @ PHARMACHEMIE EQ 10MG BASE N74539 001 Mar 31, 2003 Feb DISC

TELITHROMYCIN

TABLET; ORAL
 KETEK
 AVENTIS PHARMS 300MG N21144 002 Feb 09, 2005 Feb NEWA

TERBUTALINE SULFATE

TABLET; ORAL
 TERBUTALINE SULFATE
 AB LANNETT 2.5MG N77152 001 Mar 25, 2005 Mar NEWA
 AB 5MG N77152 002 Mar 25, 2005 Mar NEWA

TERCONAZOLE

CREAM; VAGINAL
 TERCONAZOLE
 AB ALTANA 0.4% N76712 001 Feb 18, 2005 Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
 TESTOSTERONE CYPIONATE
 AO PADDOCK 200MG/ML N40530 001 Jan 31, 2005 Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
 SUMYCIN
 @ APOTHECON 250MG N60429 001 Mar DISC
 @ 500MG N60429 003 Mar DISC
 TETRACYCLINE HCL
 AB + IVAX PHARMS 500MG N60704 002 Mar CRLD
 @ MAST MM 250MG N62085 001 Feb DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
 THEOPHYLLINE
 >D> BC INWOOD LABS 125MG N40052 002 Feb 14, 1994 Apr CTEC

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLINE

>A> INWOOD LABS 125MG N40052 002 Feb 14, 1994 Apr CTEC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA + TEVA PHARMS 30MG/ML N89602 001 Nov 09, 1987 Mar CAHN
AA + 100MG/ML N89603 001 Nov 09, 1987 Mar CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA TEVA PHARMS EQ 5MG BASE/ML N71554 001 Oct 16, 1987 Mar CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
DETROL LA

>D> + PHARMACIA AND UPJOHN 2MG N21228 001 Dec 22, 2000 Apr CRLD
>A> 2MG N21228 001 Dec 22, 2000 Apr CRLD

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON
+ GTX INC

EQ 60MG BASE N20497 001 May 29, 1997 Jan CAHN

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB ROXANE 5MG N76943 001 Mar 01, 2005 Feb NEWA
AB 10MG N76943 002 Mar 01, 2005 Feb NEWA
AB 20MG N76943 003 Mar 01, 2005 Feb NEWA

TRETINOIN

SOLUTION; TOPICAL
TRETINOIN

AT TEVA PHARMS 0.05% N74873 001 Jun 19, 1998 Mar CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL

NAQUA

@ SCHERING 4MG N12265 002 Feb DISC

TRICHLORMETHIAZIDE

@ ABC HOLDING 4MG N85568 001 Feb DISC

@ PAR PHARM 2MG N87007 001 Feb DISC

@ 4MG N87005 001 Feb DISC

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

@ TARO PHARMS NORTH EQ 25MG BASE/5ML N74374 001 Jun 23, 1995 Jan CAHN

+ EQ 50MG BASE/5ML N74973 001 Jan 24, 2000 Jan CAHN

URSODIOL

CAPSULE; ORAL
URSODIOL
AB TEVA PHARMS 300MG N75592 001 May 25, 2000 Mar CAHN

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID
AA TEVA PHARMS 250MG/5ML N73178 001 Aug 25, 1992 Mar CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN PM
ELAN PHARM 100MG N20943 001 Nov 25, 1998 Mar CRLD
200MG N20943 002 Nov 25, 1998 Mar CRLD

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE
AP AM PHARM EQ 10MG BASE/ML N76849 001 Apr 18, 2005 Mar NEWA

PREScription DRUG PRODUCT LIST - 25TH EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 4 - April 2005

2-1

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER 500MG

N21317 001 Oct 18, 2001 Mar CMFD

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

>D> + ENVIRODERM 5% N20532 001 Aug 26, 1996 Apr CAHN
>A> + STAND HOMEOPATH 5% N20532 001 Aug 26, 1996 Apr CAHN

CHLORHEXIDINE GLUCONATE

CLOTH; TOPICAL

CHLORHEXIDINE GLUCONATE

>A> + SAGE PRODS 2% N21669 001 Apr 25, 2005 Apr NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

>D> + MEDI FLEX HOSP 2%;70% N20832 001 Jul 14, 2000 Apr CTNA
>A> + MEDI FLEX INC 2%;70% N20832 001 Jul 14, 2000 Apr CTNA
>A> CHLORAPREP WITH TINT
>A> + MEDI FLEX INC 2%;70% N20832 002 May 03, 2005 Apr NEWA

CLOTRIMAZOLE

TABLET; VAGINAL

GYNIX

TEVA PHARMS 100MG

N73249 001 Feb 13, 1998 Mar CAHN

DEXTRMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

>D> + CELLTECH PHARMS EQ 30MG HBR/5ML N18658 001 Oct 08, 1982 Apr CAHN
>A> + UCB EQ 30MG HBR/5ML N18658 001 Oct 08, 1982 Apr CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

PERRIGO 10MG

N75400 001 Mar 18, 2005 Mar NEWA

WOCKHARDT 10MG

N77146 001 Mar 07, 2005 Feb NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

>A> + MCNEIL 1MG/7.5ML N19487 002 Jul 08, 2004 Apr NEWA

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

@ SCHERING 1MG/ML

N20641 003 Nov 19, 2003 Jan DISC

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE 3
TARO 4% N76773 001 Mar 02, 2005 Feb NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICOTINE POLACRILEX

>D>	WATSON LABS	EQ 2MG BASE	N76568 001 Jul 29, 2004 Apr DISC
>A>	@	EQ 2MG BASE	N76568 001 Jul 29, 2004 Apr DISC
>D>		EQ 2MG BASE	N76569 001 Jul 29, 2004 Apr CTNA
>D>		EQ 4MG BASE	N76568 002 Jul 29, 2004 Apr CTNA
>D>		EQ 4MG BASE	N76569 002 Jul 29, 2004 Apr DISC
>A>	@	EQ 4MG BASE	N76569 002 Jul 29, 2004 Apr DISC
>A>	NICOTINE POLACRILEX (MINT)		
>A>	WATSON LABS	EQ 2MG BASE	N76569 001 Jul 29, 2004 Apr CTNA
>A>		EQ 4MG BASE	N76568 002 Jul 29, 2004 Apr CTNA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2005

NO APRIL 2005 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2005 ADDITIONS

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE - ALBUTEROL SULFATE HFA						
021457 001	5605674	Feb	25, 2014	DP		
	5695743	Jul	06, 2010	DP	U-491	
	>A> 5766573	Nov	28, 2009		U-356	
	6352684	Nov	28, 2009	DP		
ALPRAZOLAM - NIRAVAM						
021726 001	6024981	Apr	09, 2018	DP		
	6221392	Apr	09, 2018	DP		
ALPRAZOLAM - NIRAVAM						
021726 002	6024981	Apr	09, 2018	DP		
	6221392	Apr	09, 2018	DP		
ALPRAZOLAM - NIRAVAM						
021726 003	6024981	Apr	09, 2018	DP		
	6221392	Apr	09, 2018	DP		
ALPRAZOLAM - NIRAVAM						
021726 004	6024981	Apr	09, 2018	DP		
	6221392	Apr	09, 2018	DP		
ARIPIPRAZOLE - ABILIFY						
021713 001				I-437	Sep 29, 2007	
				I-401	Aug 28, 2006	
				NCE	Nov 15, 2007	
ARSENIC TRIOXIDE - TRISENOX						
021248 001	6855339	Nov	10, 2018	U-617		
	6861076	Nov	10, 2018	U-617		
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
021411 007	5658590	Jan	11, 2015	U-494	NCE	Nov 26, 2007
	>A> 5658590*PED	Jul	11, 2015	PED		May 26, 2008
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
021411 008	5658590	Jan	11, 2015	U-494	NCE	Nov 26, 2007
	>A> 5658590*PED	Jul	11, 2015	PED		May 26, 2008
BEXAROTENE - TARGRETIN						
021055 001	>A> 6043279	Apr	22, 2012	U-509		
	>A> 6320074	Apr	22, 2012	DS	U-509	
BEXAROTENE - TARGRETIN						
021056 001	>A> 6043279	Apr	22, 2012	U-510		
	>A> 6320074	Apr	22, 2012	DS	U-510	
BORTEZOMIB - VELCADE						
021602 001				I-452	Mar 25, 2008	
BROMFENAC SODIUM - XIBROM						
021664 001				NP	Mar 24, 2008	
BUDESONIDE - ENTOCORT EC						
021324 001				>A> I-454	Apr 29, 2008	
CANDESARTAN CILEXETIL - ATACAND						
020838 001				I-448	Feb 22, 2008	
CANDESARTAN CILEXETIL - ATACAND						
020838 002				I-448	Feb 22, 2008	
CANDESARTAN CILEXETIL - ATACAND						
020838 003				I-448	Feb 22, 2008	
CANDESARTAN CILEXETIL - ATACAND						
020838 004				I-448	Feb 22, 2008	
CARBAMAZEPINE - CARBATROL						
020712 003	>A> 5326570	Jul	05, 2011	U-215		
	>A> 5912013	Jun	15, 2016	U-277		
CARBAMAZEPINE - EQUETRO						
021710 001	5326570	Jul	23, 2011	DP	U-627	
	5912013	Jun	15, 2016	DP		
CARBAMAZEPINE - EQUETRO						
021710 002	5326570	Jul	23, 2011	DP	U-627	
	5912013	Jun	15, 2016	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBAMAZEPINE - EQUETRO</u>					
021710 003	5326570	Jul 23, 2011	DP	U-627	
	5912013	Jun 15, 2016	DP		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>					
021485 002	>A> 5446194	Oct 19, 2013	DS		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>					
021485 003	>A> 5446194	Oct 19, 2013	DS		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>					
021485 001	>A> 5446194	Oct 19, 2013	DS		
<u>CETRORELIX - CETROTIDE</u>					
021197 001	6863891	Feb 19, 2013		U-426	
<u>CETRORELIX - CETROTIDE</u>					
021197 002	6863891	Feb 19, 2013		U-426	
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>					
020832 002				>A> NP	May 03, 2008
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>					
020805 001	>A> 4844902	Feb 11, 2008	DP		
	>A> 5843930	Jul 06, 2015		U-646	
<u>CLOFARABINE - CLOLAR</u>					
021673 001	4918179	Jun 14, 2005	DS		
	5384310	May 23, 2009	DS	DP	
	5661136	Aug 26, 2014		U-626	
<u>COLESTIPOL HYDROCHLORIDE - COLESTID</u>					
020222 001	5490987	Feb 13, 2013	DP		
<u>DAPTOMYCIN - CUBICIN</u>					
021572 001	6852689	Sep 24, 2019		U-282	
<u>DAPTOMYCIN - CUBICIN</u>					
021572 002	6852689	Sep 24, 2019		U-282	
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>					
021513 001	5096890	Mar 13, 2010	DS	DP	U-631
	6106864	Aug 21, 2016	DP		U-630
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>					
021513 002	5096890	Mar 13, 2010	DS	DP	U-631
	6106864	Aug 21, 2016	DP		U-630
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>					
021271 001				NCE	Apr 04, 2008
<u>DESLORATADINE - CLARINEX</u>					
021165 001	>A> 4659716	Apr 21, 2006		U-427	
	>A> 4659716*PED	Oct 21, 2006		U-427	
<u>DESLORATADINE - CLARINEX</u>					
021300 001	>A> 4659716	Apr 21, 2006	DP	U-611	
	>A> 4659716*PED	Oct 21, 2006			
<u>DESLORATADINE - CLARINEX</u>					
021312 001	>A> 4659716	Apr 21, 2006		U-427	
	>A> 4659716*PED	Oct 21, 2006		U-427	
<u>DESLORATADINE; PSEUDOEPHENDRINE SULFATE - CLARINEX D 24 HOUR</u>					
021605 001	>A> 4659716	Apr 21, 2006	DP	U-644	
	>A> 4659716*PED	Oct 21, 2006		NC	Dec 21, 2006
	>A> 6100274	Jul 07, 2019	DP	PED	Mar 03, 2008
	>A> 6100274*PED	Jan 07, 2020			Jun 21, 2007
<u>DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE</u>					
076068 001				PC	Aug 27, 2005
<u>DEXRAZOXANE HYDROCHLORIDE - DEXRAZOXANE</u>					
076068 002				>A> PC	Oct 19, 2005
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>					
018658 001	>A> 5980882	Apr 16, 2017	DP		
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>					
021168 001	6720004	Dec 18, 2018	DP		

PREScription AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIVALPROEX SODIUM - DEPAKOTE ER	021168 002	6720004 Dec 18, 2018		DP		
DOXAZOSIN MESYLATE - CARDURA XL	021269 001				NDF	Feb 22, 2008
DOXAZOSIN MESYLATE - CARDURA XL	021269 002	4837111 Mar 21, 2008		DP	NDF	Feb 22, 2008
ENTACAPONE - COMTAN	020796 001	>A> 5446194 Oct 19, 2013		DS		
ENTECAVIR - BARACLUDÉ	021797 001	>A> 5206244 Oct 18, 2010		DS	>A> NCE	Mar 29, 2010
ENTECAVIR - BARACLUDÉ	021797 002	>A> 5206244 Oct 18, 2010		DS	>A> NCE	Mar 29, 2010
ENTECAVIR - BARACLUDÉ	021798 001	>A> 5206244 Oct 18, 2010		DS	>A> NCE	Mar 29, 2010
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT	021504 001	6862473 Sep 30, 2013		DP		
EPLERENONE - INSPRA	021437 001	4559332 Apr 09, 2006		DS DP	U-537	
EPLERENONE - INSPRA	021437 002	4559332 Apr 09, 2006		DS DP	U-537	
EPLERENONE - INSPRA	021437 003	4559332 Apr 09, 2006		DS DP	U-537	
ERTAPENEM SODIUM - INVANZ	021337 001	5478820 Feb 02, 2013			NCE	Nov 21, 2006
		5478820*PED Aug 02, 2013			PED	May 21, 2007
		5652233 Feb 02, 2013				
		5652233*PED Aug 02, 2013				
		5952323 May 15, 2017				
		5952323*PED Nov 15, 2017				
ESMOLOL HYDROCHLORIDE - ESMOLOL HCL	076323 001				PC	May 01, 2005
ESOMEPRAZOLE MAGNESIUM - NEXIUM	021153 001	4738974 Apr 19, 2006		DS DP	U-635 U-373	
		4738974 Apr 19, 2006		DS DP	U-373	
		4738974*PED Oct 19, 2006				
		6875872 May 27, 2014		DS		
		6875872*PED Nov 27, 2014				
ESOMEPRAZOLE MAGNESIUM - NEXIUM	021153 002	4738974 Apr 19, 2006		DS DP	U-635 U-373	
		4738974 Apr 19, 2006		DS DP	U-373	
		4738974*PED Oct 19, 2006				
		6875872 May 27, 2014		DS		
		6875872*PED Nov 27, 2014				
ESOMEPRAZOLE SODIUM - NEXIUM IV	021689 001	>A> 5877192 May 27, 2014			U-643	>A> NE
		>A> 5877192*PED Nov 27, 2014				>A> NDF
		>A> 6143771 May 27, 2014		DP	U-643	
ESOMEPRAZOLE SODIUM - NEXIUM IV	021689 002	>A> 5877192 May 27, 2014			U-643	>A> NE
		>A> 5877192*PED Nov 27, 2014				>A> NDF
		>A> 6143771 May 27, 2014		DP	U-643	
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA	021443 001	6660726 Mar 08, 2021		DS DP	U-284 U-196	NP
		6660726 Mar 08, 2021		DS DP	U-196	
		6855703 Feb 12, 2021		DS DP	U-284	
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA	021443 002	6660726 Mar 08, 2021		DS DP	U-284	NP
		6660726 Mar 08, 2021		DS DP	U-196	
		6855703 Feb 12, 2021		DS DP	U-284	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
021443 003	6660726	Mar 08, 2021	DS	DP	U-284	
	6660726	Mar 08, 2021	DS	DP	U-196	
	6855703	Feb 12, 2021	DS	DP	U-284	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
021443 004	6660726	Mar 08, 2021	DS	DP	U-284	
	6660726	Mar 08, 2021	DS	DP	U-196	
	6855703	Feb 12, 2021	DS	DP	U-284	
<u>ESZOPICLONE - LUNESTA</u>						
021476 001	6319926	Jan 16, 2012			U-620	
	6444673	Jan 16, 2012	DS	DP		
	6864257	Aug 30, 2012			U-629	
<u>ESZOPICLONE - LUNESTA</u>						
021476 002	6319926	Jan 16, 2012			U-620	
	6444673	Jan 16, 2012	DS	DP		
	6864257	Aug 30, 2012			U-629	
<u>ESZOPICLONE - LUNESTA</u>						
021476 003	6319926	Jan 16, 2012			U-620	
	6444673	Jan 16, 2012	DS	DP		
	6864257	Aug 30, 2012			U-629	
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 001					>A> NCE	Apr 28, 2010
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 002					>A> NCE	Apr 28, 2010
<u>FAMOTIDINE - FLUXID</u>						
021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FENTANYL - DURAGESIC-12</u>						
019813 005					NPP PED	May 20, 2006 Nov 20, 2006
<u>FENTANYL CITRATE - ACTIQ</u>						
020747 001	5785989	May 01, 2005				
<u>FENTANYL CITRATE - ACTIQ</u>						
020747 002	5785989	May 01, 2005				
<u>FENTANYL CITRATE - ACTIQ</u>						
020747 003	5785989	May 01, 2005				
<u>FENTANYL CITRATE - ACTIQ</u>						
020747 004	5785989	May 01, 2005				
<u>FENTANYL CITRATE - ACTIQ</u>						
020747 005	5785989	May 01, 2005				
<u>FENTANYL CITRATE - ACTIQ</u>						
020747 006	5785989	May 01, 2005				
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
021737 001					>A> NDF	Apr 08, 2008
<u>FLUOCINONIDE - VANOS</u>						
021758 001					NP	Feb 11, 2008
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
021152 001					NDF PED	Mar 31, 2008 Sep 30, 2008
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
021077 001	6536427	Mar 01, 2011	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
021077 002	6536427	Mar 01, 2011	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
021077 003	6536427	Mar 01, 2011	DP			
<u>GALANTAMINE HYDROBROMIDE - REMINYL</u>						
021169 001	6358527	Jun 06, 2017	DP	U-322		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GALANTAMINE HYDROBROMIDE - REMINYL</u>						
021169 002	6358527	Jun	06, 2017	DP	U-322	
<u>GALANTAMINE HYDROBROMIDE - REMINYL</u>						
021169 003	6358527	Jun	06, 2017	DP	U-322	
<u>GEMCITABINE HYDROCHLORIDE - GEMZAR</u>						
020509 001	4808614	May	15, 2010	DS	I-428	May 19, 2007
	4808614*PED	Nov	15, 2010		>A> M-40	Apr 26, 2008
	5464826	Nov	07, 2012		>A> PED	Oct 26, 2008
	5464826*PED	May	07, 2013		PED	Nov 19, 2007
<u>GEMCITABINE HYDROCHLORIDE - GEMZAR</u>						
020509 002	4808614	May	15, 2010	DS	I-428	May 19, 2007
	4808614*PED	Nov	15, 2010		>A> M-40	Apr 26, 2008
	5464826	Nov	07, 2012		>A> PED	Oct 26, 2008
	5464826*PED	May	07, 2013		PED	Nov 19, 2007
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
020239 003	4886808	Dec	29, 2007	DS DP	U-89	I-369 Aug 16, 2005
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
020239 004					I-369	Aug 16, 2005
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
020758 004	>A> 5270317	Sep	30, 2011	DS DP		
	>A> 5270317*PED	Mar	30, 2012			
	>A> 5994348	Jun	07, 2015			
	>A> 5994348*PED	Dec	07, 2015			
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
020387 001	>A> 5138069	Aug	11, 2009	DS		
<u>HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR</u>						
020387 002	>A> 5138069	Aug	11, 2009	DS		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
021532 002	>A> 6878703	Nov	19, 2021		U-3	
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
021532 003	>A> 6878703	Nov	19, 2021		U-3	
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
021532 005	>A> 6878703	Nov	19, 2021		U-3	
<u>IBANDRONATE SODIUM - BONIVA</u>						
021455 002	>A> 4927814	Jul	09, 2007	DS DP	U-642	D-96 Mar 24, 2008
	>A> 6294196	Oct	07, 2019	DP	NS	Mar 24, 2008
					NCE	May 16, 2008
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021335 001	5521184	Jan	04, 2015			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021335 002	5521184	Jan	04, 2015			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 001	5521184	Jan	04, 2015			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 002	5521184	Jan	04, 2015			
<u>ITRACONAZOLE - ITRACONAZOLE</u>						
076104 001					PC	Aug 08, 2005
<u>LETROZOLE - FEMARA</u>						
020726 001					I-446	Oct 29, 2007
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
021731 001	4938763	Oct	03, 2008	DP	U-621	
	5278201	Jan	11, 2011	DP		
	5324519	Jun	28, 2011	DP		
	5599552	Feb	04, 2014	DP	U-621	
	5739176	Oct	03, 2008	DP	U-621	
	6395293	Sep	28, 2013	DP		
	6565874	Oct	28, 2018	DP	U-621	
	6626870	Mar	27, 2020	DP		
	6773714	Oct	28, 2018		U-621	
	RE37950	Oct	03, 2008	DP	U-621	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
021730 001	>A> 5225183	Jul 06, 2010	DP		NP	Mar 11, 2008
	>A> 5362755	Nov 08, 2011		U-636		
	>A> 5439670	Jul 06, 2010	DP			
	>A> 5547994	Aug 20, 2013		U-636		
	>A> 5605674	Feb 25, 2014	DP			
	>A> 5695743	Jul 06, 2010	DP	U-636		
	>A> 5760090	Jan 05, 2010		U-636		
	>A> 5836299	Nov 17, 2017	DP			
	>A> 5844002	Jan 05, 2010		U-636		
	>A> 6083993	Jan 05, 2010		U-636		
	>A> 6352684	Nov 28, 2009	DP			
<u>LINEZOLID - ZYVOX</u>						
021130 001	5688792	Nov 18, 2014	DS	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP		NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021			NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS		PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021			PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
<u>LINEZOLID - ZYVOX</u>						
021130 002	5688792	Nov 18, 2014	DS	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6514529	Mar 15, 2021	DP		NPP	Dec 19, 2005
	6514529*PED	Sep 15, 2021			NCE	Apr 18, 2005
	6559305	Jan 29, 2021	DS		PED	Dec 23, 2007
	6559305*PED	Jul 29, 2021			PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
<u>LINEZOLID - ZYVOX</u>						
021131 001	5688792	Nov 18, 2014		U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS		NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021			NCE	Apr 18, 2005
					PED	Dec 23, 2007
					PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
<u>LINEZOLID - ZYVOX</u>						
021132 001	5688792	Nov 18, 2014	DS	U-319	I-431	Jun 23, 2007
	5688792*PED	May 18, 2015			I-402	Jul 22, 2006
	6559305	Jan 29, 2021	DS		NPP	Dec 19, 2005
	6559305*PED	Jul 29, 2021			NCE	Apr 18, 2005
					PED	Dec 23, 2007
					PED	Jan 22, 2007
					PED	Jun 19, 2006
					PED	Oct 18, 2005
<u>LOVASTATIN - ALTOPREV</u>						
021316 001	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
021316 002	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
021316 003	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
021316 004	6485748	Dec 12, 2017	DP			
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
021583 001	6495534	May 15, 2020	DP		I-451	Mar 25, 2008
<u>MELOXICAM - MOBIC</u>						
020938 001					I-430	Jul 16, 2007
					NCE	Apr 13, 2005
					PED	Jan 16, 2008
					PED	Oct 13, 2005

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - MOBIC</u>						
021530 001	6184220	Mar	25, 2019	DP	I-430	Jul 16, 2007
	6184220*PED	Sep	25, 2019		NCE	Apr 13, 2005
					PED	Jan 16, 2008
					PED	Oct 13, 2005
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
021574 001	6866866	Mar	17, 2021	DP		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
021574 002	6866866	Mar	17, 2021	DP		
<u>METFORMIN HYDROCHLORIDE - METFORMIN HCL</u>						
076863 001					PC	Apr 12, 2005
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
019962 001	4927640	May	22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep	18, 2007	DP	U-107	
	5001161	Sep	18, 2007	DP		
	5081154	Sep	18, 2007	DS		
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
019962 002	4927640	May	22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep	18, 2007	DP	U-107	
	5001161	Sep	18, 2007	DP		
	5081154	Sep	18, 2007	DS		
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
019962 003	4927640	May	22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep	18, 2007	DP	U-107	
	5001161	Sep	18, 2007	DP		
	5081154	Sep	18, 2007	DS		
<u>METOPROLOL SUCCINATE - TOPROL-XL</u>						
019962 004	4927640	May	22, 2007	DP	D-95	Feb 15, 2008
	4957745	Sep	18, 2007	DP	U-107	
	5001161	Sep	18, 2007	DP	U-107	
	5081154	Sep	18, 2007	DS	U-107	
<u>MICAFUNGIN SODIUM - MYCAME</u>						
021506 002					NCE	Mar 16, 2010
<u>MODAFINIL - PROVIGIL</u>						
020717 001					I-449	Jan 23, 2007
<u>MODAFINIL - PROVIGIL</u>						
020717 002					I-449	Jan 23, 2007
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
021067 001	>A> 5394868	Jun	25, 2012	DP	NP	Mar 30, 2008
	>A> 5687710	Nov	18, 2014	DP		
	>A> 5829434	Nov	03, 2015	DP		
	>A> 5889015	Jan	27, 2014	U-645		
	>A> 6057307	Jan	27, 2014	DP	U-645	
	>A> 6240918	Feb	20, 2017	DP		
	>A> 6365581	Jan	27, 2014	U-645		
	>A> 6503537	Mar	17, 2018	DP		
	>A> 6677322	Jan	27, 2014	U-645		
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
020762 001	5837699	Jan	27, 2014	DP	U-625	
	6127353	Oct	03, 2017	DS	DP	
	6723713	Jan	27, 2014		U-625	
<u>NATEGLINIDE - STARLIX</u>						
021204 001	6844008	Nov	14, 2017	DP	U-214	
	RE34878	Sep	08, 2009			
<u>NATEGLINIDE - STARLIX</u>						
021204 002	6844008	Nov	14, 2017	DP	U-214	
	RE34878	Sep	08, 2009			
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)</u>						
076313 001				>A>	PC	Oct 02, 2005
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)</u>						
076313 002				>A>	PC	Oct 02, 2005

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE (PRESERVATIVE FREE)</u>					
076313 003				>A> PC	Oct 02, 2005
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 005	5753618	Jul 08, 2008			
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>					
021286 001	>A> 6878703	Nov 19, 2021		U-3	
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>					
021286 003	>A> 6878703	Nov 19, 2021		U-3	
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>					
021286 004	>A> 6878703	Nov 19, 2021		U-3	
<u>OMEPRAZOLE - ZEGERID</u>					
021706 001	5840737	Jul 16, 2016	DS	U-624	
	5840737	Jul 16, 2016	DS	U-623	
	6489346	Jul 16, 2016	DS DP	U-624	
	6489346	Jul 16, 2016	DS DP	U-623	
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016		U-624	
	6699885	Jul 16, 2016		U-623	
	6780882	Jul 16, 2016	DS DP		
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>					
020007 001				>A> D-98	Mar 25, 2008
				D-97	Mar 25, 2008
				>A> PED	Sep 25, 2008
				PED	Sep 25, 2008
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN PRESERVATIVE FREE</u>					
020007 003				>A> D-98	Mar 25, 2008
				D-97	Mar 25, 2008
				>A> PED	Sep 25, 2008
				PED	Sep 25, 2008
<u>OXALIPLATIN - ELOXATIN</u>					
021759 001			I-441 NCE		Nov 04, 2007 Aug 09, 2007
<u>OXALIPLATIN - ELOXATIN</u>					
021759 002			I-441 NCE		Nov 04, 2007 Aug 09, 2007
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 001			NCE PED		Jan 14, 2005 Jul 14, 2005
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 002			NCE PED		Jan 14, 2005 Jul 14, 2005
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 003			NCE PED		Jan 14, 2005 Jul 14, 2005
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021285 001			NCE PED		Jan 14, 2005 Jul 14, 2005
<u>PACLITAXEL - ABRAXANE</u>					
021660 001	5439686	Feb 22, 2013	DP	NP	Jan 07, 2008
	5498421	Mar 12, 2013	DP	U-634	
	6096331	Feb 22, 2013	DP	U-633	
	6506405	Feb 22, 2013	DP	U-633	
	6537579	Feb 22, 2013		U-632	
	6749868	Feb 22, 2013	DP		
	6753006	Feb 22, 2013	DP		
<u>PEGAPTANIB SODIUM - MACUGEN</u>					
021756 001	5919455	Oct 27, 2013	DS		
	5932462	Aug 03, 2016	DS		
	6011020	Jan 04, 2017	DS		
	6051698	Sep 17, 2012	DS		
	6113906	Oct 27, 2013	DS		
	6147204	Jun 11, 2010	DS		
	6426335	Jun 11, 2010		U-622	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMINTIDE ACETATE - SYMLIN</u>							
021332 001	>A> 5175145	Dec 29,	2009		U-637	NCE	
	>A> 5686411	Nov 11,	2014	DS	DP	U-638	
	>A> 5814600	Sep 29,	2015			U-639	
	>A> 5998367	Mar 08,	2011	DS	DP		
	>A> 6114304	Sep 05,	2017			U-640	
	>A> 6410511	Jan 09,	2018		DP		
	>A> 6608029	Sep 07,	2013			U-641	
	>A> 6610824	Mar 08,	2011	DS			
<u>PREGABALIN - LYRICA</u>							
021446 001	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 002	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 003	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 004	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 005	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 006	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 007	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>PREGABALIN - LYRICA</u>							
021446 008	6001876	Jul 16,	2017			U-55	
	6197819	Mar 06,	2018	DS	DP		
<u>RIBAVIRIN - COPEGUS</u>							
021511 001						I-447	Feb 25, 2008
<u>RISPERIDONE - RISPERDAL</u>							
021444 004	>A> 4804663	Dec 29,	2007	DS	DP	U-543	
	>A> 5648093	Jul 15,	2014		DP		
	>A> 6224905	Jun 10,	2017		DP		
<u>RISPERIDONE - RISPERDAL</u>							
021444 005	>A> 4804663	Dec 29,	2007	DS	DP	U-543	
	>A> 5648093	Jul 15,	2014		DP		
	>A> 6224905	Jun 10,	2017		DP		
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>							
021071 002	5002953	Aug 30,	2008	DS	DP	U-628	
	5002953	Aug 30,	2008	DS	DP	U-329	
	5741803	Apr 21,	2015	DS	DP	U-628	
	5741803	Apr 21,	2015	DS	DP	U-329	
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>							
021071 003	5002953	Aug 30,	2008	DS	DP	U-628	
	5002953	Aug 30,	2008	DS	DP	U-329	
	5741803	Apr 21,	2015	DS	DP	U-628	
	5741803	Apr 21,	2015	DS	DP	U-329	
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>							
021071 004	5002953	Aug 30,	2008	DS	DP	U-628	
	5002953	Aug 30,	2008	DS	DP	U-329	
	5741803	Apr 21,	2015	DS	DP	U-628	
	5741803	Apr 21,	2015	DS	DP	U-329	
<u>ROUVASTATIN CALCIUM - CRESTOR</u>							
021366 002	6858618	Dec 17,	2021			U-618	
<u>ROUVASTATIN CALCIUM - CRESTOR</u>							
021366 003	6858618	Dec 17,	2021			U-618	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROUVASTATIN CALCIUM - CRESTOR</u>				U-618		
021366 004	6858618	Dec	17, 2021	U-618		
<u>ROUVASTATIN CALCIUM - CRESTOR</u>				U-618		
021366 005	6858618	Dec	17, 2021	U-618		
<u>SIROLIMUS - RAPAMUNE</u>						
021083 001	>A> 5536729	Sep	30, 2013	DP	>A> NPP >A> PED	Mar 11, 2008 Sep 11, 2008
<u>SIROLIMUS - RAPAMUNE</u>						
021110 001	>A> 5989591	Mar	11, 2018	DP	>A> NPP >A> PED	Mar 11, 2008 Sep 11, 2008
<u>SIROLIMUS - RAPAMUNE</u>						
021110 002	>A> 5989591	Mar	11, 2018	DP	>A> NPP >A> PED	Mar 11, 2008 Sep 11, 2008
<u>SIROLIMUS - RAPAMUNE</u>						
021110 003	>A> 5100899 >A> 5100899*PED >A> 5212155 >A> 5212155*PED >A> 5403833 >A> 5403833*PED >A> 5989591 >A> 5989591*PED	Jun	06, 2009 Dec 06, 2009 May 18, 2010 Nov 18, 2010 Apr 04, 2012 Oct 04, 2012 Mar 11, 2018 Sep 11, 2018	U-290 U-291 U-293	>A> NPP >A> PED	Mar 11, 2008 Sep 11, 2008
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE - AMMONUL</u>						
020645 001				NDF ODE		Feb 17, 2008 Feb 17, 2012
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 001	>A> 4968299 6152897	Jun	28, 2008 Nov 20, 2018	DP DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 002	>A> 4968299 6152897	Jun	28, 2008 Nov 20, 2018	DP DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 003	>A> 4968299 6152897	Jun	28, 2008 Nov 20, 2018	DP DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 005	>A> 4968299 6152897	Jun	28, 2008 Nov 20, 2018	DP DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 008	>A> 4968299 6152897	Jun	28, 2008 Nov 20, 2018	DP DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 009	>A> 4968299 6152897	Jun	28, 2008 Nov 20, 2018	DP DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 010	>A> 4968299	Jun	28, 2008	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 011	>A> 4968299	Jun	28, 2008	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 012	>A> 4968299	Jun	28, 2008	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
020280 013	>A> 4968299	Jun	28, 2008	DP		
<u>TELITHROMYCIN - KETEK</u>						
021144 002	>A> 5635485 >A> D459798	Apr	21, 2015 Sep 24, 2015	DS DP	U-578 NCE	Apr 01, 2009
<u>TEMOZOLOMIDE - TEMODAR</u>						
021029 001	5260291 5260291*PED	Aug	11, 2013 Feb 11, 2014	DS DP	U-619 I-450 ODE	Mar 15, 2008 Mar 15, 2012
<u>TEMOZOLOMIDE - TEMODAR</u>						
021029 002	5260291 5260291*PED	Aug	11, 2013 Feb 11, 2014	DS DP	U-619 I-450 ODE	Mar 15, 2008 Mar 15, 2012

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>TEMOZOLOMIDE - TEMODAR</u>									
021029 003	5260291	Aug 11, 2013	DS	DP	U-619		I-450 ODE	Mar 15, 2008	
	5260291*PED	Feb 11, 2014						Mar 15, 2012	
<u>TEMOZOLOMIDE - TEMODAR</u>									
021029 004	5260291	Aug 11, 2013	DS	DP	U-619		I-450 ODE	Mar 15, 2008	
	5260291*PED	Feb 11, 2014						Mar 15, 2012	
<u>THALIDOMIDE - THALOMID</u>									
020785 001	>A> 6869399	Oct 23, 2020			U-371				
<u>THALIDOMIDE - THALOMID</u>									
020785 002	>A> 6869399	Oct 23, 2020			U-371				
<u>THALIDOMIDE - THALOMID</u>									
020785 003	>A> 6869399	Oct 23, 2020			U-371				
<u>TOPIRAMATE - TOPAMAX</u>									
020505 001							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX</u>									
020505 002							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX</u>									
020505 003							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX</u>									
020505 004							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX</u>									
020505 005							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX</u>									
020505 006							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>									
020844 001							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>									
020844 002							I-41		Aug 11, 2007
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>									
020844 003							I-41		Aug 11, 2007
<u>VORICONAZOLE - VFEND</u>									
021266 001	5567817	May 24, 2016	DS	DP	U-540				
<u>VORICONAZOLE - VFEND</u>									
021266 002	5567817	May 24, 2016	DS	DP	U-540				
<u>VORICONAZOLE - VFEND</u>									
021267 001	5567817	May 24, 2016	DS	DP	U-540				
<u>VORICONAZOLE - VFEND</u>									
021630 001	5567817	May 24, 2016	DS	DP	U-540				
<u>ZICONOTIDE - PRIALT</u>									
021060 001	5364842	Dec 30, 2011			U-55				
	5364842	Dec 30, 2011			U-48				
	5795864	Jun 27, 2015		DP					
	5859186	Dec 30, 2011			U-55				
	5859186	Dec 30, 2011			U-48				
<u>ZICONOTIDE - PRIALT</u>									
021060 002	5364842	Dec 30, 2011			U-55				
	5364842	Dec 30, 2011			U-48				
	5795864	Jun 27, 2015		DP					
	5859186	Dec 30, 2011			U-55				
	5859186	Dec 30, 2011			U-48				
<u>ZICONOTIDE - PRIALT</u>									
021060 003	5364842	Dec 30, 2011			U-55				
	5364842	Dec 30, 2011			U-48				
	5795864	Jun 27, 2015		DP					
	5859186	Dec 30, 2011			U-55				
	5859186	Dec 30, 2011			U-48				

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE - PRIALT</u>					
021060 004	5364842	Dec 30, 2011		U-55	
	5364842	Dec 30, 2011		U-48	
	5795864	Jun 27, 2015	DP		
	5859186	Dec 30, 2011		U-55	
	5859186	Dec 30, 2011		U-48	

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:

DS = Drug Substance claim

DP = Drug Product claim

U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at

<http://www.fda.gov/cder/orange/patex.htm>

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of Patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>